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1 Introduction 
 
 
1.1 Interleukin-6 and its receptors 
 
Interleukin-6 (IL-6) is a pleiotropic cytokine, which stimulates a variety of cells types 
including B cells, T cells, keratinocytes, neuronal cells, and endothelial cells. It plays an 
important role in host defense by regulating immune and inflammatory responses. IL-6 was 
originally identified as a factor inducing immunoglobulin production in B lymphocytes. 
Moreover, IL-6 induces expression of several acute phase proteins in the liver and functions 
as a strong hepatocyte-stimulating factor. IL-6 also stimulates thrombopoiesis and regulates 
bone resorption (112).   
IL-6 belongs to the gp130-family of cytokines comprising interleukin-11 (IL-11), leukemia 
inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), 
cardiotropin-1 (CT-1), cardiotrophin-like cytokine/neurotrophin-1/B-cell stimulating factor 3 
(CLC/NNT-1/BSF-3), new neuropoietin (NPN) and IL-27, which all utilize glycoprotein 130 
(gp130) as a common signal transducing subunit. Some of these cytokines need additional 
membrane-bound or soluble cytokine-receptor proteins to induce signaling. IL-6 first binds its 
membrane-bound α-receptor, the IL-6 receptor (IL-6R), which is not involved in signal 
transduction. Thereupon, the IL-6/IL-6R complex sequentially associates with two molecules 
of gp130. Dimerization of gp130 leads to intracellular signaling events like activation of JAK 
(Janus kinase) tyrosine kinase family members, followed by the activation of transcription 
factors of the STAT (signal transducers and activators of transcription) family and their 
subsequent transport into the nucleus. Another major signaling pathway for IL-6 is the MAPK 
(mitogen-activated protein kinase) cascade (44).  
The mature IL-6 protein is about 20-28 kDa in size, depending on the glycosylation status. It 
has been shown that IL-6 is both N- and O-glycosylated (100). It adopts the typical four-
helix-bundle fold characteristic for most hematopoietic cytokines containing four α-helices, 
which are arranged in an up-up-down-down topology (41). IL-6 engages its receptors via 
three different binding epitopes referred to as site I, II and III (Fig. 1). Site I is located at the 
C-terminus of the AB-loop and Helix D and mediates binding to the IL-6R. Site II is formed 
by residues of helices A and C, whereas site III consists of amino acids located at the N-
terminal part of the AB-loop and the beginning of Helix D (110). The sites II and III are used 
to engage and recruit gp130, with site III being unique among the gp130-family of cytokines. 
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IL-6R and gp130 are glycosylated type I membrane proteins (extracellular N-terminus, one 
transmembrane domain). Both receptors are characterized by the presence of one cytokine-
binding module (CBM) consisting of two fibronectin-type-III-like domains of which the N-
terminal domain contains a set of four conserved cysteine residues and the C-terminal domain 
a TrpSerXTrpSer (WSXWS) motif (6). IL-6R as well as gp130 contain an IgG-like domain 
located at the N-terminus of the molecule. Gp130, in contrast to IL-6R, has three additional 
membrane-proximal fibronectin-type-III-like domains (Fig. 2). The IgG-like domain of gp130 
binds to site III of IL-6, whereas the CBM of gp130 interacts with site II. Although the three 
membrane-proximal domains are not involved in ligand binding, they are necessary for 
transmitting the signal into the cell, since deletion of these domains leads to signaling 
incompetent receptors (60). Binding of the IL-6R to the ligand occurs via the CBM (domains 
2 and 3), the IgG-like domain is not involved in the engagement of IL-6 and therefore 
dispensable for biological activity (124). However, the IgG-like domain stabilizes the IL-6R 
during intracellular trafficking through the secretory pathway (119).  
Binding of IL-6 to its receptors is followed by a rapid internalization of the ligand. Within the 
IL-6R protein no internalization signal has been identified, whereas in gp130 a dileucine-like 
motif, that is required for receptor-mediated ligand internalization, has been defined (26). 
Figure 1: (A) 3D structure of IL-6. The four α-helices (A-D) as well as the binding sites to the IL-6R (site I) 
and gp130 (sites II and III) are indicated. (B) Typical up-up-down-down topology of IL-6. Site I is 
located at the C-terminus of the AB-loop and Helix D, site II at helix A and C and site III contains 
the N-terminal part of the AB-loop and the beginning of Helix D (104). 
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1.2 IL-6-transsignaling and the designer cytokine Hyper-IL-6 
 
Most soluble cytokine receptors (e.g. IL-1R, TNFR and IL-4R) exhibit antagonistic properties 
by competing with their membrane-bound counterparts for the respective ligands (25, 39, 
120). In contrast, the soluble IL-6R (sIL-6R) acts as an agonist of IL-6 activity. While gp130 
is found on all cell types, expression of the IL-6R is largely confined to hepatocytes and some 
leukocyte subpopulations (112). Cells lacking IL-6R do not respond to IL-6. A naturally 
occuring soluble form of the IL-6R, which is found in various body fluids of healthy humans 
(25-35 ng/ml in serum), can render these cells responsive to IL-6. Thereby, sIL-6R binds IL-6 
in solution with the same affinity as membrane-expressed IL-6R and the complex of IL-6 and 
sIL-6R can stimulate cells lacking membrane-bound IL-6R (Fig. 3). This alternative IL-6 
signaling pathway, based on the agonistic properties of the sIL-6R, has been termed 
transsignaling (54, 98, 99, 104). In addition, IL-6-responsive cells are sensitized by the 
presence of the sIL-6R protein (89). Among the cell types that can only be activated by IL-6 
in the presence of the soluble IL-6R are embryonic stem cells (97), early hematopoietic 
Figure 2: Domain structure of gp130 (green) and IL-6R (blue). Each domain contains roughly 100 amino 
acids. CBM: Cytokine-binding module. FN III: Fibronectin-type-III-like domains. PM: Plasma 
membrane. Ig: IgG-like domain. 
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progenitor cells (90), neural cells (65-67), smooth muscle cells (56), osteoclasts (113) and 
endothelial cells (96). In principle, due to the ubiquitous expression of gp130, the IL-6/sIL-6R 
complex can stimulate virtually all cells of the body. Soluble IL-6R is generated either by 
limited proteolysis of the membrane-bound protein (78) or by translation from an alternatively 
spliced mRNA (64). Although the two isoforms of the sIL-6R are structurally and 
functionally closely related, the cellular release of both forms seems to be differentially 
regulated (52). In humans, the alternatively spliced variant can be distinguished from the shed 
form by a novel proximal COOH-terminal sequence (GSRRRGSCGL), which is introduced 
during the splicing process (48). Shedding of the IL-6 receptor is triggered by different stimuli 
such as phorbol ester (79), bacterial metalloproteinases and pore-forming toxins (121), C-
reactive-protein (53), cholesterol depletion (68) and apoptosis (13). Induced cleavage of the 
IL-6R is mediated by the metalloprotease TACE (ADAM17), whereas constitutive shedding 
is dependent on ADAM10 (68). 
 
 
gp130
IL-6R
sIL-6R
IL-6 IL-6/sIL-6R
 
 
 
 
 
 
Figure 3: IL-6-transsignaling. A soluble form of the IL-6R (sIL-6R), which is generated via shedding 
from the membrane surface or alternative splicing, activates cells lacking the membrane-
bound IL-6R. Virtually all cells of the body can be stimulated. 
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In order to mimic IL-6-transsignaling a designer cytokine, designated Hyper-IL-6, was 
constructed. Hyper-IL-6 is a fusion protein built up of IL-6 and the sIL-6R connected via a 
flexible peptide linker (Fig. 4), which prevents the natural dissociation-association of the 
ligand-receptor complex (31). In case of Hyper-IL-6 signaling only occurs via the sIL-6R. It 
turned out, that Hyper-IL-6 was 100-1000 times more active on gp130-expressing cells (e.g. 
hematopoietic progenitor cells) than the combination of IL-6 and the sIL-6R (31). Moreover, 
Hyper-IL-6 has been used to succesfully treat acute liver failure in mice and rats (34, 35, 87). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to the IL-6R also the second component of the IL-6 receptor complex, gp130, 
exists in a soluble form (sgp130). Relatively high circulating levels of sgp130 are detected in 
human blood (100-400 ng/ml) and sgp130 may associate with the IL-6/sIL-6R complex to 
inhibit signaling via membrane-bound gp130 (74, 80, 82, 123) (Fig. 5). It has been concluded 
that sgp130 is the natural inhibitor of IL-6-transsignaling and that sgp130 acts as a buffer to 
prevent the stimulation of virtually all cells in the body by the IL-6/sIL-6R complex (55).  
 
Figure 4: Molecular model of Hyper-IL-6. Hyper-IL-6 consists of IL-6 (grey) and the sIL-6R 
(yellow) fused by a flexible peptide linker. A, B, C and D are the four α-helices of 
IL-6, D-II and D-III denote the two ligand binding domains of the IL-6R (31). 
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Interestingly, it has been found that sgp130 also blocks LIF- and OSM-signaling although to a 
much lesser extent (55, 105). 
Similar to the sIL-6R, both proteolytic cleavage and alternative splicing have been implicated 
in the cellular liberation of sgp130 (52, 81). On the other hand, it has been shown that after 
phorbol ester stimulation proteolytic cleavage of gp130 was considerably less than observed 
for the IL-6R (76) suggesting that alternative splicing and not shedding is the main 
mechanism responsible for sgp130 release. Recently, a 50-kDa isoform of sgp130 was 
identified as an autoantigen in rheumatoid arthritis (114). This alternatively spliced protein 
Figure 5: Inhibition of IL-6-transsignaling. Soluble gp130 associates with the IL-6/sIL-6R complex and 
thereby prevents activation of cells which lack membrane-bound IL-6R. The IL-6/sIL-6R complex 
can bind to membrane-bound gp130 equally. Therefore a molar excess of sgp130 is needed for  
competitive inhibition (A). Classical IL-6-signaling remains unaffected, since sgp130 cannot bind to 
IL-6 in solution (B).  
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harbours a unique COOH-terminal sequence (NIASF) and a high incidence of serum 
antibodies against this sequence have been detected in patients suffering from rheumatoid 
arthritis. Gp130-RAPS (gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble 
form) has been shown to bind with high affinity to Hyper-IL-6 and to effectively modulate 
leukocyte migration in a murine peritonitis model (94). 
A variant of sgp130 was constructed in our group by fusing the complete extracellular region 
of gp130 (domains D1-D6) with the Fc-part of a human IgG-antibody (Fig. 6). The resulting 
protein, called sgp130Fc, is a preformed dimer and therefore strongly resembles the receptor 
conformation on the living cell. It has been shown that dimerized sgp130Fc is able to inhibit 
IL-6/sIL-6R-mediated responses with a 10-fold higher activity than monomeric sgp130 (55). 
Thus, classic IL-6-signaling and IL-6-transsignaling can easily be distinguished with the help 
of sgp130Fc. 
COOH
NH2
NH2
COOH
sgp130 IgG-Fc
 
 
 
 
 
 
1.3 Pathophysiology of IL-6-transsignaling 
 
Elevated levels of sIL-6R have been detected in several inflammatory and neoplastic 
disorders and it has been shown that IL-6-transsignaling is involved in the pathogenesis as 
well as in the persistence of these diseases (54). 
Figure 6: Sgp130Fc is a preformed dimer consisting of the extracellular part of gp130 fused to 
the Fc portion of a human IgG1 antibody. 
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In inflammatory bowel disease, which is a chronic inflammatory disease of the 
gastrointestinal tract, sIL-6R mediated signaling contributes to the increased resistance of 
mucosal T cells against apotosis. In these cells signal transducer and activator of transcription 
3 (STAT-3) as well as the anti-apoptotic genes bcl-2 and bclxl are highly upregulated. In vivo 
administration of recombinant sgp130Fc leads to T-cell apoptosis and suppression of colitis 
activity indicating that IL-6-transsignaling accounts for both development and perpetuation of 
chronic intestinal inflammation (4).  
Elevated sIL-6R concentrations have been observed in the joints of patients suffering from 
arthritis, with the highest levels being detected in the more progressive stages of rheumatoid 
arthritis (59, 95). In addition, a strong correlation between the infiltration of leukocytes into 
arthritic joints and increased sIL-6R levels in the synovial fluid was found (23). Induction of 
arthritis (both antigen-induced and collagen-induced) in IL-6-knockout mice resulted in no 
clinical signs or in significantly reduced disease (2, 9). Intra-articular administration of 
Hyper-IL-6, in contrast to IL-6 alone, restored full disease activity in IL-6-knockout mice 
demonstrating that sIL-6R signaling is involved in the pathogenesis of rheumatoid arthritis. In 
addition, neutralization of IL-6-transsignaling in wild-type mice using sgp130Fc protein 
ameliorated the disease (85). 
Recent studies have shown that sIL-6R mediated events control leukocyte infiltration in 
murine models of acute inflammation (49, 96). It was demonstrated in several in vitro studies 
that IL-6 in combination with sIL-6R can activate various cell types to produce a certain 
subset of chemokines (IL-8, MCP-1 and MCP-3) and adhesion molecules (ICAM-1 and 
VCAM-1) (49, 56, 58, 73, 96). Later it became evident that the IL-6/sIL-6R complex plays an 
important role in regulating the switch between the early, predominantly neutrophilic stage of 
an infection/inflammation and the more sustained mononuclear cell influx (54). 
In colon cancer the expression of both IL-6 and sIL-6R is drastically increased (109). IL-6 can 
promote the growth of colon cancer cells and enhanced IL-6 levels were found to correlate 
with tumor size (17, 33). In a murine colitis-associated colon carcinoma model, treatment 
with an anti-IL-6R-antibody as well as sgp130Fc significantly reduced tumor number and size 
indicating that IL-6-transsignaling promotes colon carcinogenesis in mice (7). Interestingly, 
the IL-6R is completely lost on epithelial tumor cells most likely due to proteolytic cleavage 
by the metalloproteinase ADAM17 (8). It turned out that during colon carcinogenesis IL-6-
transsignaling is controlled by infiltrating CD4+CD8+-T lymphocytes via a TGFβ-related 
mechanism, as transgenic mice overexpressing TGFβ had less tumors and mice with a 
deficient TGFβ-T cell response showed enhanced tumor development (7). 
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Furthermore, soluble IL-6R-signaling has also been implicated in the pathogenesis of asthma 
(28), ileitis, which is a form of intestinal inflammation (72), and multiple myeloma (32, 42). 
 
 
1.4 Viral IL-6 
 
Viral IL-6 (vIL-6) is encoded by human herpesvirus 8 (HHV 8), which is associated with 
Kaposi sarcoma (KS) and lymphoproliferative disorders, such as pleural effusion lymphoma 
and multicentric Castleman’s disease (75, 83, 84). The viral homologue shares 25% amino 
acid identity with human IL-6 and it turned out that both cytokines utilize the gp130 receptor 
system (12, 45). In contrast to human IL-6, which requires binding to the IL-6R before 
engaging gp130, vIL-6 can directly associate with gp130 (47, 62, 77).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The solution of the 3D structure of vIL-6 in complex with the extracellular portion of gp130 
revealed that two vIL-6 molecules are complexed in a ring-like fashion with two molecules of 
gp130. The structure also shows that vIL-6 binds gp130 via site II (engages the CBM of the 
first gp130) and site III (associates with D1 of the second gp130), whereas site I remains 
Figure 7: 3D structure of vIL-6 (red and magenta) in complex with the domains D1-D3 of 
gp130 (blue and green). The signaling complex is a tetramer consisting of two 
molecules of vIL-6 and gp130 (16). 
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unoccupied (16). So far, vIL-6 is the only naturally occuring cytokine which directly binds 
and activates gp130. Like the IL-6/sIL-6R complex vIL-6 is able to stimulate virtually all 
cells in the body and therefore mimicks IL-6-transsignaling (57, 77).  
It turned out that vIL-6 effectively blocks a major antiviral immune mechanism induced by 
IFN signaling. In infected cells IFN-α normally leads to p21 mediated cell cycle arrest and 
downregulation of membrane-bound IL-6R, thereby rendering the cells unresponsive to the 
proliferative effects of IL-6. Viral IL-6, which can activate gp130 expressing cells that lack 
the cognate IL-6R, is still able to mediate signal transduction and activation of these cells by 
creating an autocrine secretion loop (14).  
Analogous to the IL-6/sIL-6R complex, the biological activity of vIL-6 can be completely 
inhibited by sgp130Fc (77).    
  
 
 
 
  
 
 
 
 
 
 
 
Figure 8: Model for HHV8 vIL-6 mediated inhibition of IFN-α signaling. The vIL-6 promoter is 
activated by IFN-α, vIL-6 protein is produced allowing infected cells to proliferate, 
albeit IFN-α leads to IL-6R (gp80) downregulation (14). 
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1.5 Aim of this work 
 
To investigate the pathophysiological consequences of IL-6-transsignaling in vivo, transgenic 
mice were constructed and characterized, which overexpress sgp130Fc from a liver-specific 
promoter. High levels of transgenic sgp130Fc could be detected in the serum of these mice 
and it was demonstrated that the protein was functionally active. A murine model of acute 
inflammation was employed and it turned out that in sgp130Fc-transgenic mice leukocyte 
recruitment was profoundly impaired, indicating that IL-6-transsignaling plays an important 
role in the resolution of inflammation.  
Sgp130Fc transgenic animals are therefore an ideal tool to study the pathophysiology of sIL-
6R-mediated responses in vivo, as they reflect an “IL-6-transsignaling knock out” situation in 
mice.  
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2 Material and Methods 
 
2.1 Material 
 
Chemicals: 
 
All chemicals used were from ROTH, SIGMA or MERCK. If it is not mentioned otherwise 
deionized water (Millipore) was used as solvent.  
 
Bacterial strains and cell lines: 
 
- E. coli DH5α (Invitrogen)   
- E. coli XL1 blue (Stratagene) 
- HepG2, human hepatocarcinoma cell line (ATCC) 
 
Vectors: 
 
- pTZ-pEPCK-βglob.intron : vector used for transgene generation (89) 
- p409-sgp130Fc, p409-sgp130Fc/opt : eukaryotic expression vectors 
 
Primer: 
 
- SAA2-forward: 5`- TCA CCA GCC TGG TCT TCT G-3` 
- SAA2-reverse: 5`- CTG AGC TAA TAG GAG GAC G-3` 
- sgp130Fcopt-forward: 5`- GAG TTC AGA TCC TGC GAC-3` 
- sgp130Fcopt-reverse: 5`- TCA CTT GCC AGG AGA CAG-3` 
All primers used in this work were purchased from METABION. 
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Antibiotics: 
 
- Ampicillin 50 µg/ml in H2O 
- Kanamycin 50 µg/ml in H2O 
 
Media: 
 
- LB-Medium:  5 g/l yeast extract, 10 g/l tryptone, 10 g/l NaCl 
- LB-Agar: 5 g/l yeast extract, 10 g/l tryptone, 10 g/l NaCl, 15g/l agar 
- Cell growth medium: DMEM High Glucose Culture Medium (PAA), 10% FCS, 60 
mg/l penicillin, 100 mg/l streptomycin 
 
Enzymes: 
 
All used restriction enzymes and DNA polymerases (Taq, Pfu and T4), as well as T4 DNA 
Ligase, calf intestine alkaline phosphatase (CIAP) and T4 polynucleotidkinase were 
purchased from Fermentas. 
 
Enzyme substrates: 
 
- Substrate Reagent Pack (R&D Systems) - 3,3`-5,5`-Tetramethylbenzidine, horseradish   
peroxidase substrate for ELISA 
- ECL plus Western blotting detection system (Amersham) 
 
Antibodies: 
 
- Mouse anti-human sgp130 BP-4 (Diaclone), diluted 1:1,000 
- Mouse anti-human sIL-6R clone 14-18, 1:10,000 (produced in our laboratory)  
- Anti-mouse IgG goat peroxidase conjugate (Pierce), 1:10,000 
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- Alexa Fluor 488-conjugated anti-mouse Ly-6G and Ly-6C (BD Pharmingen), 1:400 
 for Flow Cytometry  
- APC-conjugated  anti-mouse F4/80 (Caltag), 1:400 for Flow Cytometry 
- Purified anti-mouse CD16/CD32 (FcγIII/II Receptor, mouse Fc block, BD 
Pharmingen), 1:500 for Flow Cytometry 
- purified anti-mouse Ly-6GC (BD Pharmingen), 0.1 mg/mouse i.p., for neutrophil 
depletion in mice 
- PE-conjugated anti-mouse B220 (BD Pharmingen), 1:400 for Flow Cytometry 
- FITC-conjugated anti-mouse CD3 (BD Pharmingen), 1:200 for Flow Cytometry 
 
 
Recombinant cytokines: 
 
- Hyper-IL-6  (100 ng/µl), prepared and purified as described in (31)   
- human IL-6 (100 ng/µl), prepared and purified as described in (117)   
- human sgp130Fc (100 ng/µl), prepared and purified as described in (55)   
 
Molecular markers: 
 
- Protein molecular weight marker (Fermentas) 
- Prestained protein molecular weight marker (Fermentas) 
- GeneRuler 1 kb DNA Ladder (Fermentas) 
- Gene Ruler 100bp Ladder (Fermentas) 
 
Radiochemicals: 
 
Deoxyadenosine-5`-triphosphate, [α-32P], 3000 Ci/mmol was purchased from MP 
Biomedicals. 
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Membranes: 
 
- Hybond-N+ (Amersham), positively charged nylon membran 
- Hybond-P (Amersham), PVDF membrane 
 
Kits: 
 
- NucleoSpin RNA II (Macherey-Nagel) 
- QIAquick PCR Purification Kit (Qiagen) 
- QIAquick Gel Extraction Kit (Qiagen) 
- NucleoBond PC 100 DNA PurificationKit (Macherey-Nagel) 
- DuoSet human gp130 ELISA Kit (R&D Systems) 
- Duo Set mouse IL-6 ELISA Kit (R&D Systems) 
- DuoSet mouse KC ELISA Kit (R&D Systems) 
- Ready-SET-Go! mouse MCP-1 ELISA Kit (eBiosciences) 
- Mouse IL-6R ELISA Kit (developed by S. Jones, Cardiff) 
- Prime-It II Random Primer Labeling Kit (Stratagene) 
 
Buffers: 
 
- TBS: 50 mM Tris-HCl pH 7.6, 200 mM NaCl 
- TBS-T: 50 mM Tris-HCl pH 7.6, 200 mM NaCl, 0.05% Tween-20 
- PBS: 250 mM NaCl, 20 mM KCl, 48 mM Na2HPO4, 1.5 mM KH2PO4 pH 7.4 
- PBS-T: 250 mM NaCl, 20 mM KCl, 48 mM Na2HPO4, 1.5 mM KH2PO4 pH 7.4,  
0.05% Tween-20 
- 0.5x TBE: 45 mM Tris-borate, 1 mM EDTA pH 8.0  
- Flow Cytometry antibody buffer: 1x PBS, 1% BSA, N3Na (1g/l) 
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- 20x SSC: 3 M NaCl, 0.3 M sodium citrate pH 7.0 
- Southern/Northern blot hybridization solution (18): 0.5 M Na2HPO4, 7% SDS, 1 mM 
EDTA, 1% BSA, pH 7.2 
- Southern blot denaturation solution: 1.5 M NaCl, 0.5 M NaOH 
- Southern blot neutralization solution : 1.5 M NaCl, 1 M Tris-HCl pH 7.0 
- Southern/Northern blot stripping buffer: 15 mM NaCl, 0.1x SSC, 1% SDS 
- 5x MOPS : 0.1 M MOPS pH 7.0, 40 mM sodium acetate, 5 mM EDTA pH 8.0  
- 2x SDS gel-loading buffer (61):  100 mM Tris-HCl pH 6.8, 4% SDS, 
0.2% bromphenol blue, 20% glycerol 
- 10%-SDS-electrophoresis seperating gel: 4.05 ml H2O, 2.5 ml 1.5 M Tris-HCl pH 8.8,  
100 µl 10% SDS, 3.3 ml 30% acrylamid/0.8% bisacrylamid, 50 µl 10% APS, 5 µl 
TEMED 
- 4%-SDS-electrophoresis stacking gel: 3.725 ml H2O, 0.625 ml 0.5 M Tris-HCl pH 6.8, 
50 µl 10% SDS, 0.67 ml 30% acrylamid/0.8% bisacrylamid, 25 µl 10% APS, 5 µl 
TEMED 
- Tris-glycine SDS-electrophoresis buffer: 25 mM Tris-base, 250 mM glycine pH 8.3, 
0.1% SDS 
- Coomassie staining solution: 1g/l Coomassie R250, 40% methanol, 10% acetic acid 
- Destaining solution: 40% methanol, 10% acetic acid 
- Western blot transfer buffer: 39 mM glycine, 48 mM Tris-base, 20% methanol 
- Western blot stripping buffer: 2% SDS, 62.5 mM Tris-base, 100 mM β-
mercaptoethanol 
- 10x IP-buffer: 0.25 M Tris-HCl pH 7.5, 5% Triton-X100, 5% NP-40 
- IP-Washing buffer A: 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.2 % NP-40, 2 mM 
EDTA 
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- IP-Washing buffer B: 10 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.2 % NP-40, 2 mM 
EDTA 
- Tail buffer: 50 mM Tris-HCl pH 8.0, 1 mM EDTA, 20 mM NaCl, 1% SDS, 100 µg/ml 
Proteinase K  
 
Animals: 
 
- Wildtype mice: C57BL/6 (Charles River, Germany) 
- Founder mice: B6D2F1 (Biotechnologielabor, Universität Heidelberg) 
 
Animal food: 
 
The standard feed as well as the protein rich/carbohydrate low diet was obtained from 
SSNIFF. 
 
Standard : crude protein  19 % 
 crude fat  3.30 % 
 crude fibre  4.90 % 
 crude ash  6.70 % 
 
Protein rich/ 
carbohydrate low: casein   64 % 
 crude fibre  22 % 
 vegatable oil  11 % 
 brewer`s yeast 2 % 
 
 
Additives: Vitamin A: 15.000 IE/kg; Vitamin D3: 1.000 IE/kg; Vitamin E: 100 mg/kg;                    
Cu: 5 mg/kg 
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2.2  Methods 
 
2.2.1  Agarose gel electrophoresis 
 
DNA gel electrophoresis was performed at 100V for 45 min in 0.5x TBE buffer. DNA-
Fragments >700 bp were seperated on 1% agarose gels, whereas fragments <700 bp were 
seperated on 2% agarose gels. DNA was stained with Ethidiumbromide (0.5 µg/ml) and 
visualized under UV-light (312 nm). If necessary, the desired fragments were cut out with a 
sterile scalpel and DNA was isolated using the QIAquick Gel Extraction Kit (Qiagen) 
following the manufacturer`s instructions. 
 
2.2.2  Cloning 
 
Plasmids were isolated either by Alkaline lysis according to Sambrook et al. (103) or, if high 
purity or quantity was needed, using the NucleoBond PC 100 DNA Purification Kit 
(Macherey-Nagel). Restriction digests and DNA ligations were carried out using the 
appropriate buffers and enzymes from Fermentas according to the manufacturer`s 
instructions.  
 
2.2.3   Polymerase Chain Reaction (PCR) 
 
The Polymerase Chain Reaction is an elegant and effective method to selectively amplify a 
desired target DNA from only a few molecules. If the PCR product was subcloned, Pfu 
polymerase (Fermentas) was employed, which exhibits an intrinsic proof reading activity, 
otherwise Taq Polymerase (Fermentas) was used.  
 
 
Standard PCR reaction settings: 5x Taq Polymerase buffer 5 µl 
     MgCl2  (25 mM)  4 µl 
     dNTPs (10 mM)  1 µl 
     Primer A (100 pmol)  0.5 µl 
     Primer B (100 pmol)  0.5 µl 
     Taq-Polymerase (2.5 U/µl) 1 µl 
     DNA Template   10-100 ng 
     H2O    ad 50 µl 
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Standard PCR programm : 94°C  2 min   initial denaturation step 
 
    94°C  30 sec   denaturation 
    55°C  30 sec  x30 primer annealing 
    72°C  1 min   elongation (1 min/1 kb) 
 
    72°C  5 min   final elongation step  
 
If necessary, the standard PCR program was modified, depending on the size and frequency 
of the amplified fragment, and on the T
m 
of the primers.  
 
 
2.2.4  RT-PCR 
 
RT-PCR is a PCR amplification of a product from the reverse transcription (RT) reaction, 
whereby a template mRNA is translated into a single-stranded cDNA. RevertAid M-MuLV 
Reverse Transcriptase from Fermentas was employed according to the manufacturer`s 
instructions. The reactions were performed using oligo(dT) primer targeting the 3’ poly(A) 
mRNA tail. The PCR settings were described above.  
 
 
2.2.5  Transformation of bacteria 
 
Plasmid DNA or ligations were transformed via heatshock. In brief, 50 µl stored chemically 
competent bacterial cells DH5α were thawn on ice and added to the chilled DNA samples, 
mixed and incubated for 5 min. Transformation was achieved at 42°C for 60 sec. After an 
additional 5 min incubation step on ice, 300 µl LB-Medium without antibiotic were added to 
the sample and incubated at 37°C for 1 h under continous shaking to allow the bacteria to 
recover. The transformed bacterial cells were then plated onto LB agar containing the 
selective antibiotic and grown over night at 37°C.  
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2.2.6 Transient transfection of HepG2 cells with DEAE 
Dextran 
 
HepG2 cells were splitted and grown to be 70-80% confluent in DMEM High Glucose 
Culture Medium (PAA) supplemented with 10% FCS and 1% penicillin/streptomycin at 37°C 
with 5% CO2 in a humidified atmosphere. Before transfection, the culture medium was 
changed to medium containing 75 µM Chloroquin. For one 10 cm cell culture dish, 5 µg of 
the appropriate plasmid DNA was thoroughly mixed with 435 µl Chloroquin-containing 
medium and 65 µl DEAE-Dextran (4 mg/ml). The mixture was dropwise added to the cells 
followed by 4-6 h incubation at 37°C. Then the culture medium was removed and the cells 
were treated with medium containing 10% DMSO for 7 min at room temperature. 
Subsequently the cells were washed with PBS and new medium was added. The next day, the 
medium was exchanged again. 
 
 
2.2.7  Serum/Plasma preparation from whole mouse blood 
 
Whole mouse blood was collected either by tail bleeding or cardiac puncture. The blood was 
allowed to clot for 2-3 h at room temperature or over night at 4°C. Afterwards, the serum was 
seperated by centrifugation (10 min, 2,600 rpm, room temperature) and then stored at –20°C. 
If Plasma was needed, 10 µl 0.5 M EDTA were added to the blood to prevent clotting. Plasma 
was obtained by centrigation (10 min, 13,000 rpm, 4°C) and stored at –20°C.  
 
 
2.2.8  Immunoprecipitation with Protein A Sepharose 
 
Protein A binds to the Fc region of immunoglobulins. Sgp130Fc is a fusion protein containing 
the Fc portion of a human IgG1 antibody and can therefore be precipitated with Protein-A-
Sepharose. To precipitate sgp130Fc from transfected HepG2 cell supernatant 10 ml 
conditioned medium was cleared from cell debris by centrifugation (5 min at 1,000 rpm) and 
ultrafiltration (0.22 µm) and incubated with 50 µl Protein-A-Sepharose (50% slurry in PBS) 
over night rolling at 4°C. On the next day the Protein-A-Sepharose was washed twice with 1 
ml IP-Washing buffer A and twice with 1 ml IP-Washing buffer B. After addition of 50 µl 2x 
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SDS gel-loading buffer and heating for 5 min at 95°C the sample was loaded on a 10% 
polyacrylamide gel. Sgp130Fc was detected by Western blotting with the mAB BP-4.  
For the precipitation of Hyper-IL-6 with transgenic sgp130Fc, 40 µl mouse serum was 
incubated with 900 µl 1x PBS, 100 µl 10x IP-buffer and 0.5 µg Hyper-IL-6 at 4°C over night 
under continous rolling. On the next day, 30 µl Protein-A-Sepharose was added to pull down 
sgp130Fc and incubated for 2 h at 4°C, again under continous rolling. The Protein-A-
Sepharose was washed and treated as described above. Detection of the co-precipitated 
Hyper-IL-6 occured with mAB sIL-6R clone 14-18, which was produced in our laboratory. 
Transgenic sgp130Fc was precipitated from mouse serum by mixing 50 µl serum with 900 µl 
1x PBS, 100 µl 10x IP-buffer and 30 µl Protein-A-Sepharose followed by incubation at 4°C 
over night. Treatment of the Protein-A-Sepharose and detection of the protein proceeded as 
described above.  
 
 
2.2.9  Western blot analysis 
 
The samples containing either sgp130Fc or Hyper-IL-6 were seperated on 10% 
polyacrylamide gels for 1.5 h at 200 V. Protein Transfer onto a PVDF membrane was 
performed at 15 V for 90 min. The membrane was blocked in 6% dry, low fat milk/TBS for 1 
h at room temperature followed by over night incubation with the primary antibody diluted in 
1% milk/TBS-T at 4°C. After intensive washing with TBS-T the membrane was incubated 
with the secondary POD conjugated antibody at room temperature for 1 h. Afterwards the 
membrane was washed repeatedly (3x 15 min TBS-T and finally 5x5 min TBS) and the 
peroxidase substrate ECL(+) was applied. X-Ray film was exposed to the chemiluminescent 
signal. 
 
 
2.2.10 Enzyme-linked Immunosorbent Assay (ELISA) 
 
The ELISAs for KC, murine MCP-1, murine IL-6, murine IL-6R and human sgp130 were 
performed according to the manufacturer`s instructions. For the human sgp130 ELISA 
recombinant sgp130Fc was used as a standard with the highest concentration being 10 ng/ml. 
Standard and serum samples were diluted with 10% FCS/1x PBS. 
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2.2.11 Southern blot analysis of genomic mouse DNA 
 
0.5 cm of the mouse tail was cut with steril scissors at the age of 3-4 weeks. The tail was 
shaken at 55°C over night in Tail buffer containing Proteinase K until the tissue was 
completely dissolved. After two phenol/chloroform/isoamylalcohol (25:24:1) purification 
steps and one chloroform extraction the DNA was precipitated with 96% Ethanol. The DNA 
sample was centrifuged (20 min, 13,000 rpm) at room temperature, the pellet was washed 
once with 70% Ethanol and thereafter air dried for 1-2 h under a fume hood. DNA was 
dissolved in 100 µl H2O over night at room temperature. The concentration of genomic 
DNA was measured by UV-spectrophotometry. 5-10 µg DNA were digested with the 
restriction endonuclease NcoI (“first” generation of sgp130Fc transgenic mice) or XhoI 
(“second” generation of codon-optimized sgp130Fc transgenic mice) and seperated on a 1% 
agarose gel for 90 min at 100 V. The gel was treated with 0.25 M HCL for 15 min, 2x 15 
min with southern blot denaturation solution and finally with southern blot neutralization 
solution for 10 min. DNA fragments were transferred from the agarose gel to a positively 
charged nylon membrane by Southern blotting (111). The capillary blot was assembled and 
performed according to Sambrook et al. (103), resulting in immobilization of the DNA 
fragments on the nylon membrane. Additionally, DNA was crosslinked to the membrane by 
UV radiation. Thereupon, the nylon membrane was hybridized with a α-32P-dATP-labeled 
probe (consisting of a XbaI-fragment comprising the entire sgp130Fc cDNA for the „first“ 
generation or a XhoI-fragment covering the entire codon-optimized sgp130Fc cDNA for the 
“second” generation of sgp130Fc transgenic mice) in prewarmed southern blot hybridization 
solution under continous rolling at 65°C over night. The radioactive labeled probe was 
generated with the Prime-It II Random Primer Labeling Kit (Stratagene) according to the 
manufacturer`s instructions. To remove excess probe, the membrane was repeatedly washed 
with 2x SSC, 0.1% SDS (moderate stringency) and 0.1x SSC, 0.1% SDS (high stringency) 
at 65°C under rolling conditions. The target sequence was visualized on X-ray film by 
autoradiography. The same nylon membrane could be used for several consecutive 
hybridizations with different probes. For successful removal of probes the filter was treated 
with a 1% SDS solution for 30 min at 80°C. 
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2.2.12 Northern blot analysis  
 
Appropriate mouse organs were excised and immediately frozen in liquid nitrogen to prevent 
degradation of the RNA by almost omnipresent RNases. Thereafter, the frozen mouse tissue 
was disrupted by grinding with a pestle and mortar in the presence of liquid nitrogen. The 
homogenized organs were subsequently processed or kept at –70°C for long-term storage. It 
was taken care that the organs did not thaw during or after the grinding. Total RNA was 
isolated with the NucleoSpin RNA II  Kit (Macherey-Nagel) and the RNA concentration was 
determined by UV-spectrophotometry. The RNA was seperated under denaturing conditions 
on a 1% agarose gel containig 7% formaldehyde. Electrophoresis was carried out in 1x MOPS 
buffer for 80 min at 100 V. To avoid RNA degradation all buffers and solutions were treated 
with 0.05% diethylpyrocarbonate (DEPC) over night at 37°C and subsequently autoclaved for 
20 min (DEPC derivitizes histidine residues and is therefore an effective method to inactivate 
RNAses). The gel was soaked over night in DEPC H2O under gentle agitation to remove 
formaldehyde. Total RNA was visualized under UV-light. Intact RNA should yield two sharp 
rRNA bands, with the 28S band being about twice as intense as the 18S band. Before 
assembling the blot the gel was equilibrated in 20x SSC for 45 min under cautious shaking. 
The physical set-up for Northern transfer was identical to that for Southern transfer (see 
above) except that 20x SSC was used as transfer buffer. RNA was fixed on the filter through 
UV-crosslinking and then hybridized with a radioactive labeled DNA probe. The probe was 
prepared with the Prime-It II Random Primer Labeling Kit (Stratagene) corresponding to the 
manufacturer`s instructions based upon a purified PCR-Fragment of the mouse SAA2 gene or 
a XhoI restriction fragment comprising the entire sgp130Fc/opt cDNA, depending on the 
purpose of the experiment. Hybridization and washing of the filter was achieved as described 
for Southern blotting. The desired target RNA was visualized on X-ray film by 
autoradiography. 
 
 
2.2.13 Murine air pouch model of acute inflammation 
 
Animals used throughout the air pouch experiments were 8-10 weeks old male C57BL/6 mice 
(Charles River), homozygous sgp130Fc-transgenic mice of the lines opt2 and opt3 (with 
sgp130Fc serum levels above 25 µg/ml) or their wildtype littermates. The air pouch model of 
local inflammation was performed according to Edwards et al. (29). Mice were anesthetized 
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with ether and subcutaneous dorsal pouches were generated by injection of 6 ml sterile air. 
After three days the pouches were reinjected with 4 ml of air. On day 6, 1 ml of a suspension 
of 1% Carrageenan (SIGMA) in sterile PBS (PAA) was injected into the cavity, whereas 
corresponding control animals received sterile PBS. Carrageenan is composed of mainly 
sulfated polysaccharides, which are generally extracted from seaweed. Injection of 
Carrageenan into air pouches of rats and mice is a well established disease model of acute, 
local inflammation (22, 29, 107). At different time points following Carrageenan challenge, 
mice were sacrificed and the pouches were washed with 3 ml ice-cold PBS. Exudates were 
collected and the volume was recorded. Total cell number was counted with a Neubauer cell-
counter chamber. The remaining lavage fluid was centrifuged at 5,000 rpm for 10 min at 4° C, 
and the supernatant was stored at –20°C until analyzed by ELISA. Levels of chemokines and 
cytokines/soluble cytokine receptors were determined using commercial ELISA Kits. 
Aliquots of the exudate containing 2x105 cells were used for Flow Cytometry analysis, 
whereby the mABs Ly6GC (BD Pharmingen), F4/80 (Caltag), CD3 (BD Pharmingen) and 
B220 (BD Pharmingen) were employed to count infiltrating neutrophils, macrophages, T cells 
and B cells, respectively.  
 
 
 
 
Figure 9:   Schematic representation of the air pouch time schedule. At different time points after Carrageenan 
injection the pouch was washed with 3 ml PBS and the exudate was analyzed by FACS or ELISA. 
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2.2.14 Neutrophil depletion  
 
8-10 weeks old male C57BL/6 mice with 6-day-old air pouches received an i.p. injection of 
100 µg purified anti-mouse Ly6GC mAB (BD Pharmingen) 18 h prior to 1% Carrageenan 
challenge. The exudates were collected 24 h and 72 h after Carrageenan injection and 
processed and analyzed as described above. 
 
 
2.2.15 Analysis of the air pouch exudate by Flow Cytometry 
 
The cells in the lavage fluid were counted with a Neubauer cell-counter chamber and 2x105 
cells were used for Flow Cytometry analysis. Cells were washed once with 500 µl Flow 
Cytometry antibody buffer and centrifuged for 5 min at 1,000 rpm. To block Fc-receptors on 
neutrophils and macrophages the cell suspension was incubated for 5 min with Mouse BD Fc 
Block CD 16/32 mAB (1:500 diluted in 100 µl Flow Cytometry antibody buffer). After 
adding antibodies all incubation and centrifugation steps were carried out at 4°C. Since 
Mouse BD Fc Block does not need to be washed off before staining, the cells were 
subsequently treated with the fluorescence-coupled mABs against Ly6GC or F4/80 for 1 h in 
order to specifically detect neutrophils and macrophages, respectively (1:400). B cells and T 
cells were stained in such a way with fluorescence-coupled mABs against B220 (CD45R) and 
CD3, respectively (1:400 and 1:200). To prevent bleaching of the antibody-conjugated 
fluorescent dye the reaction tubes were protected from direct light. Cells were washed once 
with 500 µl Flow Cytometry antibody buffer followed by centrifugation for 5 min at 1,000 
rpm and finally resuspended in 1 ml antibody buffer. Afterwards, the stained cells were 
analyzed by Flow Cytometry. 
The forward scatter/side scatter (FSC/SSC) plot revealed that the cellular distribution in the 
air pouch roughly resembles the situation observed in peripheral blood. Both cellular debris 
and Carrageenan particles could be excluded from the measurement by setting an appropriate 
gate, being sure that only intact cells were applied for Flow Cytometry analysis (Fig. 10). In 
general, data were acquired from 10,000 gated events per sample. 
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In Fig. 11 a typical histogram of Ly6GC-stained cells is depicted, which shows a distinct, 
high-fluorescent peak representing the neutrophil population in the air pouch. In contrast, the 
unstained cells did not exhibit any specific fluorescence. For quantitative Flow Cytometry 
analysis only the high-fluorescent cells were regarded as neutrophils. 
 
 
 
 
Figure 10:    Forward scatter/side scatter (FSC/SSC) plot showing the cellular distribution in the air pouch 12 h after 
induction of inflammation through 1% Carrageenan injection (one representative C57BL/6 animal). 
Each dot represents one cellular event. FSC is proportional to cell size, SSC to cell granularity. Due to 
the early stage of inflammation a prominent population of neutrophils appears in the middle of the 
diagram. The gate P1 was set to exclude both cellular debris and Carrageenan particles. 
Figure 11:    Flow Cytometry analysis (FITC-Channel) of neutrophils obtained from the pouch 
exudate of a representative C57BL/6 mouse, 12 h after Carrageenan injection.      
(A) Unstained cells. (B) Ly6GC-stained cells.  
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Since F4/80-staining did not yield such a clear and dinstinct peak, the proportion of 
macrophages was calculated from the difference in the fluorescence signal by comparing 
stained and unstained cells (Fig. 12). 
 
 
 
 
 
 
 
 
2.2.16 Intraperitoneal injection 
 
400 µl sterile PBS containing either purified anti-Ly6GC (neutrophil depletion) or 
recombinant Hyper-IL-6 (acute phase induction) were injected into the peritoneal cavity of an 
ether anesthetized mouse. To induce an acute phase response mice were treated 
intraperitoneally with 0.5 µg Hyper-IL-6. 4 h after cytokine injection animals were sacrificed 
and the liver was removed. To deplete the neutrophils in the air pouch 100 µg of purified anti-
Ly6GC mAB were injected i.p. 18 h before Carrageenan challenge. Solutions were prepared 
and loaded under a sterile fume hood. Intraperitoneal injection was performed using a 1ml 
syringe in combination with a 27 gauge needle. 
 
 
 
Figure 12:    Flow Cytometry analysis (APC-Channel) of macrophages obtained from the pouch 
exudate of a representative C57BL/6 mouse, 12 h after Carrageenan injection. 
(A) Unstained cells. (B) F4/80-stained cells.  
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2.2.17 Statistical analysis 
 
Data are expressed as mean values ± SD; 4-7 mice were used per experimental group. 
Statistical analysis were performed by using a Student’s unpaired t test 
(http://www.physics.csbsju.edu/stats/t-test.html). A p-value below 0.05 was considered 
statistically significant and denoted with one asterisk (*), whereas a p-value below 0.01 was 
indicated with two asterisks (**). 
 
2.2.18 Animal treatment 
 
Procedures involving animals and their care were conducted in conformity with national and 
international laws according to home office approved project license 66-6/06 from 9/15/2006. 
Mice were maintained in a 12 h light-dark cycle under standard conditions and were provided 
with food and water ad libitum. All mice were maintained under barrier conditions and were 
pathogen free as assessed by regular microbiological screening. The animals were kept at 
21°C ± 2°C and 60 % ± 5% humidity in individually ventilated cages (IVC). 
 
2.2.19 DNA microinjection 
 
Microinjection of DNA into the pronucleus of a fertilized mouse egg is the method most 
extensively used in the production of transgenic mice. At best, the injected DNA integrates 
into the chromosomal DNA at the one-cell stage of the zygote and the transgenic mouse 
expresses the injected DNA in every cell including germ cells.  For microinjection the vector 
containing the transgene DNA was cleaved with the appropriate restriction enzyme and the 
restriction fragment comprising the transgene was seperated on a 1% agarose gel and purified 
with the QIAquick Gel Extraction Kit (Qiagen). Transgene DNA was dissolved in 5 mM Tris-
HCl (pH 7.4), 0.1 mM EDTA and afterwards filtered to remove particles (0.22 µm). The 
microinjection was carried out at the Biotechnologielabor (BTL) of the University of 
Heidelberg. 
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2.2.20 Animal breeding 
 
The transgene DNA was injected into B6D2F1 donor embryos. B6D2F1 is a hybrid strain 
created by a cross of a C57BL/6 (B6) female and a DBA/2 (D2) male mouse. B6D2F1 mice 
are heterozygous for B6 and D2 alleles at all loci in their genome. B6D2F1 mice are 
particulary suitable for DNA microinjection because of the increased fecundity, litter size, 
body weight, resistance to disease and overall life span compared to the inbred strains used to 
create it. After microinjection, viable zygotes were implanted into the oviducts of 
pseudopregnant foster mothers and the offspring was analyzed. Integration of the transgene 
was detected both by genomic Southern blotting and PCR using DNA isolated from tail 
biopsies of 3 to 4 week old mice. Founder animals were intercrossed with C57BL/6 mice to 
establish different transgenic lines. Once a transgenic line was established, heterozygous 
animals were crossed with each other to produce homozygous mice. This implicates that the 
homozygous transgenic animals used in this study were on a mixed genetic background. 
Therefore wild-type offspring of heterozygotes were used to establish a colony of genetically 
matched littermates, which were used as control animals throughout this work. 
Since homozygous animals contain twice as much transgene DNA as heterozygous animals, 
homozygous mice can be discriminated from heterozygous by Southern blotting with the 
homozygous mice yielding twofold higher signal intensity compared to heterozygous animals. 
Moreover, homozygousity was verified through backcrossing with C57BL/6 wildtyp animals 
(the complete offspring of a homozygous mouse mated with a wildtype animal should be 
heterozygous).   
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3 Results 
 
3.1 The “first generation” of sgp130Fc-transgenic mice 
 
3.1.1 Cloning of the transgene expression vector 
 
The vector pTZ-pEPCK-βglob.intron was successfully used before to generate sIL-6R 
transgenic mice by pronuclear injection of DNA (89). sIL-6R transgenic mice have been 
shown to express the transgenic protein in large amounts (4-8 µg/ml) in the serum (91). 
Therefore the plasmid pTZ-pEPCK-βglob.intron was used to generate a construct suitable for 
high expression of sgp130Fc in mice. The vector was opened with XbaI and a XbaI restriction 
fragment comprising the entire cDNA of human sgp130Fc, derived from the vector p409-
sgp130Fc, was inserted.   
 
sgp130Fcp409 p409
XbaI XbaI
sgp130Fc
XbaI XbaI
pTZ18R
β-glob polyAPEPCK
XbaI XbaI
pTZ18R pTZ18R
PEPCK β-glob polyA
XbaI
pTZ18R
Ligation
p409-sgp130Fc pTZ-pEPCK-βglob.intron
PEPCK
XbaI
pTZ18R β-glob polyAsgp130Fc
XbaI
pTZ18R
pEPCK-sgp130Fc
PEPCK rat PEPCKpromoter β-glob
2nd intron 
rabbit β-globin polyA
polyA 
rabbit β-globin
 
 
Figure 13: Cloning scheme for the vector pEPCK-sgp130Fc used for DNA microinjection. 
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In the resulting expression vector pEPCK-sgp130Fc the cDNA coding for sgp130Fc is under 
the transcriptional control of the rat Phosphoenolpyruvate-carboxykinase (PEPCK) promoter, 
which has been shown to be active mainly in liver and – to a lesser extent – in kidney (70). 
PEPCK is the main regulatory enzyme of hepatic gluconeogenesis and catalyzes the first 
committing step in gluconeogenesis, the conversion of oxaloacetate to phosphoenolpyruvate. 
Since the PEPCK promoter is neonatally active, possible negative effects of the transgene 
could only arise after birth (43). The polyA addition signal and the second intron of the rabbit 
β-globin gene, which are located behind the transgene, have been included into the expression 
vector to enhance mRNA stability and expression efficiency (86, 102). Fig. 14 shows the 
organization of the pEPCK-sgp130Fc expression cassette with all relevant regions and 
restriction sites. 
PEPCK sgp130Fc β-glob polyA
BamHI BamHI
XbaI XbaI XhoI
NcoI NcoI
4275 bp
2446 bp
 
 
 
 
3.1.2 Generation of sgp130Fc transgenic mice 
(1rst generation) 
 
DNA microinjection of the BamHI restriction fragment comprising the sgp130Fc expression 
cassette and subsequent zygote implantation yielded 42 animals. Genetic screening for 
transgene integration into the mouse genome was carried out by Southern blotting as 
described in Material and Methods, whereby seven transgenic founder animals could be 
detected (16.7% transgene transmission). Most commonly transgenes insert randomly as 
head-to-tail concatamers into a single site in the genome and it is not unusual to find 50 or 
more copies of the transgene at the integration site (19). As seen in the Southern analysis (Fig. 
Figure 14: Organization of the pEPCK-sgp130Fc expression cassette. 
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15) the founder mice differ with respect to the signal intensity indicating that different copy 
numbers of the transgene have integrated into the genome. 
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Each founder animal was crossed with a C57BL/6 wildtype mouse to establish different 
transgenic lines, which were designated with L1-L7. To exclude the possibility of multiple 
integration sites, Southern analysis was also performed on the F1 litters to determine the 
segregation pattern of the transgene.  
The lines L2, L5 and L7 were discarded during breeding due to the low transgenic protein 
levels detected in the serum or to bad breeding performance. The lines L1, L3, L4 and L6 
were bred to homozygousity by mating two heterozygous animals of each transgenic line (in 
Fig. 16, by way of example, a breeding scheme for line L3 is outlined). 
Figure 15: Southern analysis showing the seven transgenic founder animals (L1-L7) resulting from 
DNA microinjection. 10 µg of genomic DNA was digested with NcoI and hybridized with a 
radioactive labeled probe consisting of the entire sgp130Fc cDNA. The absence of signals 
in the screened wildtype animals (WT) shows the high specificity of the employed DNA 
probe. 100 pg BamHI restriction fragment of the vector pEPCK-sgp130Fc used for 
microinjection was included as a positive control. 
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3.1.3 Serum expression of transgenic sgp130Fc  
 
Sgp130Fc is expressed under the transcriptional control of the PEPCK promoter, which is 
mainly active in liver and kidney. Since the liver exhibits a high synthetic capacity, transgenic 
proteins driven by the PEPCK promoter have been shown to be secreted at high amounts into 
the circulation (89). Therefore the serum levels of sgp130Fc were examined in homozygous 
animals. Sgp130Fc was precipitated from mouse serum with Protein A sepharose (binds the 
Figure 16: Breeding to homozygousity, as exemplified by line L3. The founder animal is intercrossed with a 
C57BL/6 wildtype mouse and two heterozygous littermates were bred to produce homozygous mice. 
Homozygous animals were mated to obtain exclusively homozygous offspring. In addition, the 
homozygous parents were crossed with C57BL/6 wildtype animals to test for true homozygousity. 
The breeding scheme is depicted on the left side with the corresponding Southern blots on the right. 
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Fc part of sgp130Fc) and detected by immunoblotting with a human sgp130-specific 
antibody.  
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The highest concentration of sgp130Fc was observed in the serum of the lines L1 and L4, 
whereas line L3 showed a moderate, and line L6 the lowest expression of the transgene (Fig. 
17). In order to quantify the exact serum levels of the transgenic protein, a commercial 
sgp130 sandwich ELISA (R&D) was employed. The sgp130Fc concentrations were in the 
high nanogram range. Consistent with the Western blot data, the highest transgene levels were 
measured in the lines L1 (0.39 µg sgp130Fc/ml serum) and L4 (0.55 µg/ml). Line 6 showed 
the weakest expression with 60 ng/ml serum (Fig. 18). 
Remarkably, there was no obvious correlation between the copy number and the expression 
level of the transgene. Animals belonging to line L6 showed the lowest sgp130Fc serum 
levels. On the contrary, this line exhibited the strongest signal seen in the Southern analysis 
indicating a high copy number of the transgene. Moreover, the lines L1 and L4, which had the 
highest serum concentrations of sgp130Fc, only showed moderate signals in the Southern 
blot. 
Figure 17: Detection of  transgenic sgp130Fc in the serum of homozygous animals of the lines L1, L3, 
L4 and L6. Two mice per transgenic line were shown. As a positive control different 
amounts of recombinant sgp130Fc were included. In wildtype (WT) serum no sgp130Fc 
was found. The smaller band in the serum samples represents unspecific binding of the 
antibody, since it appears in the wildtype animal as well.    
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The PEPCK promoter can be activated via dietary changes. During periods of fasting, 
starvation or intense exercise the body produces glucose from non-sugar carbon substrates 
like pyruvate, lactate, glycerol and amino acids (gluconeogenesis). For this reason it was 
possible to additionally increase the expression of sgp130Fc by feeding the mice a protein 
rich/carbohydrate low diet. Supplying the mice for two weeks with special food containing 
low amounts of carbohydrates resulted in a strong increase in protein expression (Fig. 19). 
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Figure 18: Serum levels of sgp130Fc in homozygous animals of the lines L1, L3, L4 and L6 as 
measured by sgp130 sandwich ELISA. Four animals per line were analyzed. Data represent 
mean values ± SD. 
 
 
Figure 19: Comparison of  normal and carbohydrate low diet (three mice per group). When 
homozygous mice of line L4 were fed for two weeks a special carbohydrate low diet, 
sgp130Fc serum concentration considerably increased. Sgp130Fc was precipitated 
with Protein A sepharose and detected by immunoblotting. WT wildtype animal. 
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3.1.4  Induction of the acute phase response via intra-
peritoneal injection of Hyper-IL-6  
 
One of the most prominent features of IL-6 is its strong ability to stimulate the hepatic acute 
phase reaction in response to infection, physical trauma or malignancy (38). The acute phase 
response is characterized by changes in the plasma concentration of various so-called acute 
phase proteins (APPs), which are predominantly produced by the liver. Serum amyloid A 
(SAA) is a major acute phase protein in mice, which is induced up to a 1,000-fold under acute 
inflammatory conditions following exposure to bacterial lipopolysaccharides (125). Hyper-
IL-6 is a strong inducer of the acute phase reaction as well and it turned out that the acute 
phase response, when compared to IL-6, is markedly increased and lasts significantly longer 
(88). In this experiment wildtype and homozygous sgp130Fc transgenic mice of line L4, 
which displayed the highest expression of sgp130Fc protein among the four transgenic lines, 
were injected intraperitoneally with 400 ng Hyper-IL-6. After four hours mice were sacrificed 
and the liver was removed. Total liver RNA was isolated and mRNA expression of the major 
acute phase protein SAA2 was monitored by Northern blotting (Fig. 20A). 
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Figure 20: (A) Northern blot showing the liver expression of the APP serum amyloid A (SAA2) in two wildtype and 
three homozygous sgp130Fc transgenic mice of line L4 4 h after i.p. injection of 400 ng Hyper-IL-6. 
Transgenic mice were fed a carbohydrate low diet for two weeks. A wildtype animal (WT) injected with 
the same volume PBS served as a negative control. 5 µg total liver RNA were seperated on a 1% 
formaldehyde containing agarose gel and probed with a 32P-labeled PCR fragment of the mouse SAA2 
gene. (B) Sgp130Fc selectively inhibited the acute phase response induced by Hyper-IL-6. HepG2 cells 
were stimulated with 100 ng/ml of IL-6 or Hyper-IL-6 for 18 h in the presence or absence of 1 mg/ml 
sgp130Fc. Unstimulated cells treated with or without sgp130Fc were used as control (co). Secretion of 
the APP a1-antichymotrypsin was analyzed by immunoblotting. Data taken from (55)  
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It was previously shown in vitro that sgp130Fc is able to selectively inhibit the acute phase 
response elicited by Hyper-IL-6, whereas the acute phase induced by IL-6 remained 
unaffected (Fig. 20B) (55).  
Injection of Hyper-IL-6 into wildtype mice resulted in a strong induction of the acute phase 
protein SAA2. When sgp130Fc transgenic animals of line L4 were challenged with the same 
amount of Hyper-IL-6, no significant difference in terms of SAA expression was observed 
compared to wildtype mice. Intraperitoneal injection of the carrier solution (PBS) caused no 
response indicating that the injection per se did not lead to a stimulation of the acute phase 
reaction. Taken together, these results suggest that the amounts of sgp130Fc present in the 
circulation of homozygous animals of line L4 were not sufficient to block the acute phase 
response induced by Hyper-IL-6.   
 
 
3.2 The “second generation” of sgp130Fc transgenic mice 
 
A molar excess of sgp130Fc is needed for an effective inhibition of IL-6-transsignaling, as 
sgp130Fc has to compete with the membrane-bound gp130 for the IL-6/sIL-6R complex (55). 
Although the expression of sgp130Fc could further be enhanced by feeding the mice a 
carbohydrate low diet, the amounts of circulating sgp130Fc in the transgenic mice were 
nevertheless too low to inhibit the Hyper-IL-6-induced acute phase response. In particular, 
when considering microenvironments as the knee joint, where high levels of sIL-6R (24.7 
ng/ml) have been detected in rheumatoid athritis patients (23), it is important to have 
sufficient serum levels of sgp130Fc to effectively block sIL-6R mediated signaling in such 
closed compartments within the mouse. In order to achieve higher serum concentrations of 
sgp130Fc, transgenic mice were generated, which express sgp130Fc from a codon-optimized 
cDNA. 
 
 
3.2.1 Codon-optimization of the sgp130Fc cDNA 
 
Codon-optimization was performed by the biotech company GENEART (Regensburg). The 
codon usage of sgp130Fc was adapted to the codon bias of mammalian genes, i.e. only the 
most frequently occuring codons in mammalian genomes were used. By increasing the 
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translation efficiency – without altering the amino acid sequence - the optimized gene should 
allow high and stable expression rates in human as well as in rodent cells. 
 
 
 
 
 
 
 
 
 
Figure 21: Codon usage of the optimized gene (sgp130Fc) compared to the wildtype sequence: the most 
frequently used codon was set to 100 and the remaining were scaled accordingly (“relative 
adaptiveness”). The histograms represent the overall codon frequency within the coding region; 
e.g. red bars indicate the frequency of extremely rare codons. 
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In addition, regions of very high (>80%) or very low (<30%) GC content were avoided where 
possible, thereby increasing mRNA half-life.  
 
 
 
 
 
 
 
 
 
 
During the optimization process, the following cis-acting sequence motifs, which may 
negatively influence the expression, were eliminated: 
 
Figure 22: GC content of the optimized gene (sgp130Fc) compared to the wildtype sequence: The plot 
represents the GC content at the indicated sequence position 
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- internal TATA-boxes, chi-sites (recombinational hotspots) and ribosomal entry 
sites 
- AT-rich or GC-rich sequence stretches 
- repeat sequences and RNA secondary structures 
- cryptic splice donor and acceptor sites, branch points 
- reverse-complementary sequence identities longer than 20 nucleotides 
(to avoid RNA interference) 
 
 
As a result of the cDNA optimization ∼ 23% of the wildtype nucleotides were exchanged. 
Moreover, for an efficient translational termination a second stop codon was added and a 
Kozak-consensus sequence (short) was introduced upstream of the starting ATG in order 
to improve translational initiation. 
Additional information is available on the homepage of GENEART (www.geneart.com). 
  
 
3.2.2 Cloning of the transgene expression vector, part II 
 
Beside the codon-optimization of the sgp130Fc cDNA, we chose an additional method to 
enhance the expression of the transgene. It is known that genomic constructs (containing 
introns and exons) were expressed more efficiently in transgenic mice than constructs lacking 
introns (10). Further improvement of expression efficiency could be achieved when 
heterologous introns were inserted between promoter and the transgene, and not 3` of the 
coding region (86). Therefore, the codon-optimized cDNA of sgp130Fc was cloned between 
the 2nd intron and the polyA addition signal of the rabbit β-globin gene. The vector pTZ-
pEPCK-βglob.intron was opened with XhoI and then ligated with a XhoI restriction fragment 
comprising the entire optimized sgp130Fc cDNA, which was derived from the vector p409-
sgp130Fc/opt (Fig. 23A). Moreover, optimized sgp130Fc was inserted between the rat 
PEPCK promoter and the 2nd β-globin intron. For this purpose the vector pTZ-pEPCK-
βglob.intron was digested with XbaI, made blunt-ended with T4 DNA Polymerase and then 
ligated with a blunt PmeI restriction fragment, that was also derived from the vector p409-
sgp130Fc/opt and contained the complete sgp130Fc/opt cDNA (Fig. 23B). Thus, in the two 
resulting constructs the optimized sgp130Fc cDNA was located in front of as well as behind 
the 2nd β-globin intron.   
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Figure 23: Cloning scheme for the vectors pEPCK-sgp130Fc/opt-XhoI (A, optimized sgp130Fc cDNA located 
behind the intron) and pEPCK-sgp130Fc/opt-XbaI (B, optimized sgp130Fc cDNA located in front of 
the intron). The XbaI restriction sites in the resulting pEPCK-sgp130Fc/opt-XbaI vector are 
destroyed due to blunting of the DNA after digestion. 
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Finally, for a proper comparison of the effect resulting from codon-optimization with the 
position effect of the intron the wildtype human sgp130Fc cDNA was cloned behind the 2nd 
β-globin intron. Therefore, the transgene expression vector pTZ-pEPCK-βglob.intron was 
cleaved with XhoI and subsequently blunted with T4 DNA Polymerase. A blunt PmeI 
restriction fragment comprising the entire wildtype sgp130Fc cDNA, originated from the 
vector p409-sgp130Fc, was then ligated into the opened vector (Fig. 24).  
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Figure 24: Cloning scheme for the vector pEPCK-sgp130Fc-XhoI (wildtype sgp130Fc cDNA, located 
behind the intron). The XhoI restriction sites in the resulting pEPCK-sgp130Fc-XhoI vector 
are destroyed due to blunting of the DNA after digestion. 
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3.2.3 Comparative expression of optimized sgp130Fc in vitro 
 
The original expression vector pEPCK-sgp130Fc, which was previously used in this work to 
generate sgp130Fc transgenic mice, and the three derivates pEPCK-sgp130Fc-XhoI, pEPCK-
sgp130Fc/opt-XhoI and pEPCK-sgp130Fc/opt-XbaI were transiently expressed in the human 
hepatoma cell line HepG2. As expression of sgp130Fc in this vector is driven by the rat 
pEPCK promoter, which has been shown to be specific in liver and kidney, the liver cell line 
HepG2 is an ideal model system to monitor sgp130Fc expression in vitro. A simplified 
schematic representation of the four different sgp130Fc transgene expression cassettes is 
given in Fig. 25A.  
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Figure 25: (A) Different transgene expression cassettes. The constructs differ in 1. the position of the intron (in 
front of/behind the transgene) and 2. in the optimization status (wildtype/optimized cDNA). 1. 
pEPCK-sgp130Fc, 2. pEPCK-sgp130Fc-XhoI, 3. pEPCK-sgp130Fc/opt-XbaI, 4. pEPCK-
sgp130Fc/opt-XhoI. (B) Different expression levels of the sgp130Fc constructs in transfected HepG2 
cell supernatant. Sgp130Fc was precipitated from cell supernatant with Protein A sepharose and 
detected by immunoblotting 
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To analyze and compare the expression of the four different transgene expression constructs 
in vitro, sgp130Fc protein was precipitated from 10 ml transfected HepG2 cell supernatant 
with Protein A Sepharose and detected by Western blotting. As depicted in Fig. 25B, the 
strongest expression was observed when codon-optimized sgp130Fc was located behind the 
2nd β-globin intron. A clearly weaker expression was found when wildtype sgp130Fc was 
cloned behind the intron. However, when the transgene was located in front of the 2nd β-
globin intron, expression of sgp130Fc was hardly detectable in HepG2 supernatant.  
Since the pEPCK-sgp130Fc/opt-XhoI expression vector led to the highest expression rates of 
sgp130Fc in vitro, this construct was used to create the „second generation” of sgp130Fc 
transgenic mice. In Fig. 26 a schematic diagram of the pEPCK-sgp130Fc/opt-XhoI expression 
cassette is depicted, which shows all relevant functional regions and restriction sites. 
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3.2.4 Generation of sgp130Fc transgenic mice, part II 
  
For the generation of codon-optimized sgp130Fc transgenic mice the EarI restriction fragment 
containing the full sgp130Fc/opt expression cassette was injected into the pronuclei of 
fertilized mouse eggs. From 128 pups, which arose from DNA microinjection, 14 were tested 
as transgene positive by Southern blotting and PCR (10.9% transgene transmission). Due to 
the high number of putative founder animals sgp130Fc serum expression was assessed and 
only the founders with the highest transgene expression were used for further breeding. Four 
different transgenic lines were established (as described in 3.1.2.), which were designated as 
opt1, opt2, opt3 and opt4. As seen in the Western blot in Fig. 27, the four transgenic lines 
apparently show different sgp130Fc serum levels with the highest sgp130Fc concentration 
Figure 26: Schematic organization of the transgene expression cassette pEPCK-sgp130Fc/opt-XhoI. 
 
3  Results   
 48
being observed in the serum of the founder animal of line opt2. The amounts of transgenic 
sgp130Fc in the serum of the remaining founders opt1, opt3 and opt4 were roughly the same, 
whereas sgp130Fc expression in line opt3 appeared to be slightly stronger than in the lines 
opt1 and opt4.  
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The highest sgp130Fc expression among the four transgenic lines of the first generation of 
sgp130Fc transgenic mice was measured in line L4. The homozygous animal of line L4, 
which was included in the Western blot analysis as a positive control, only yielded a faint 
band indicating a relatively weak sgp130Fc expression compared to the lines opt1-4. It is also 
worth mentioning that in contrast to the L4 animal the founder animals of the lines opt1-4 
were only heterozygous and therefore tended to produce rather lower amounts of the 
transgene. However, by comparing the sgp130Fc serum levels of the first sgp130Fc 
transgenic mice with the founder animals of the newly generated transgenic mice it clearly 
turned out that cDNA codon-optimization together with an altered position of the intron led to 
a potent amplification of transgenic sgp130Fc expression. The lines opt2 and opt3, which 
showed the highest sgp130Fc serum expression, were bred to homozygousity. In contrast, the 
transgenic lines opt1 and opt4 were discarded due to a bad breeding performance and to 
comparatively low sgp130Fc serum levels.  
Figure 27: Different sgp130Fc levels in the serum of the founder animals of the lines opt1-4.  Serum of a 
homozygous animal of the line L4 (first sgp130Fc transgenic mice) and 10 ng recombinant 
sgp130Fc were included as positive controls. Animals indicated with -/- were either wildtype 
animals or mice, which were tested positive for the transgene by PCR or Southern blot but failed 
to produce the transgenic protein. Sgp130Fc was precipitated from serum with Protein A 
sepharose and detected by immunoblotting. 
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3.2.5 Serum expression of transgenic sgp130Fc 
 
As mentioned above, sgp130Fc expression could be markedly increased in the newly-created 
codon-optimized sgp130Fc transgenic mice. The exact serum concentrations of sgp130Fc in 
the remaining lines opt2 and opt3 were quantified by sgp130 sandwich ELISA (R&D), as 
shown in Fig. 28.  
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Figure 28: Varying sgp130Fc serum concentrations in heterozygous (+/-) and homozygous (+/+) animals 
of the lines opt2 (A) and opt3 (B) as measured by ELISA. Each bar represents one mouse.  
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Taken together, for both lines the transgene serum levels of homozygous mice were 
significantly higher when compared to the heterozygous littermates. The sgp130Fc serum 
concentrations in the homozygous animals were in the 20-40 microgram range. The highest 
levels were measured in homozygous animals of line opt3 (34.3 ± 3.3 µg/ml serum), whereas 
sgp130Fc serum concentration in homozygous animals of line opt2 was only marginally 
below this value (27 ± 4.4 µg/ml).  
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By breeding the transgenic mice to homozygousity sgp130Fc expression in animals of the line 
opt3 could be amplified by the factor 4 (8.4  34.3 µg/ml). All heterozygous as well as all 
homozygous mice of the line opt3 showed similar sgp130Fc serum levels indicating a stable 
expression pattern of the transgene. In contrast, the situation observed in opt2 heterozygous 
mice was more complex, since sgp130Fc expression in the heterozygous animals was 
somewhat variable, albeit the mean sgp130Fc levels in heterozygous mice of both lines were 
in the same range. Some of the opt2 heterozygous mice reached the sgp130Fc concentrations 
obtained for homozygous animals, whereas other values were only in the high nanogram 
range. This inconsistent expression pattern obtained for heterozygous animals of line opt2 is 
reflected by the relatively large error bar shown in Fig. 29. Interestingly, the expression level 
Figure 29: Mean sgp130Fc serum concentration in heterozygous (+/-) and homozygous (+/+) animals of 
the lines opt2 and opt3 as measured by ELISA. Data represent mean values ± SD. n mice per 
group. 
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of sgp130Fc were similar in the different opt2 homozygous mice. When comparing 
homozygous mice of the “first” with homozygous animals of the “second generation”, a more 
than 50-fold increase of sgp130Fc protein in the serum was achieved.   
 
 
3.2.6 Differential tissue expression of transgenic sgp130Fc 
 
It has been reported that transgenic proteins under the control of the PEPCK promoter were 
mainly expressed in liver and – to a lesser extent – in kidney (70). To examine the transgene 
expression profile in sgp130Fc transgenic mice, total RNA was isolated from liver, kidney, 
spleen, lung, brain, muscle, gut and thymus. Sgp130Fc mRNA expression was assessed by 
Northern blotting using a sgp130Fc-specific probe (Fig. 30). 
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Consistently, sgp130Fc expression was found mainly in liver and kidney. However, 
appreciable amounts of sgp130Fc mRNA could also be detected in lung and muscle. Little or 
no sgp130Fc expression was observed in spleen, brain, gut and thymus. 
 
 
 
Figure 30: Northern blot showing sgp130Fc mRNA expression in different organs of two homozygous 
transgenic mice. 8 µg total liver RNA were seperated on a 1% formaldehyde containing 
agarose gel and then hybridized with a 32P-labeled XhoI restriction fragment comprising the  
complete sgp130Fc/opt cDNA. 
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3.2.7 Transgenic sgp130Fc is functionally active 
 
3.2.7.1 Transgenic sgp130Fc can precipitate Hyper-IL-6  
 
Hyper-IL-6, which is a fusion protein consisting of IL-6 and sIL-6R (see introduction), is 
known to bind sgp130Fc in solution. To test if the sgp130Fc protein produced by transgenic 
mice was functionally active, serum of both wildtype and transgenic mice was mixed with 
recombinant Hyper-IL-6. Transgenic sgp130Fc was then precipitated from serum with Protein 
A sepharose and the co-precipitated Hyper-IL-6 was detected by immunoblotting (Fig. 31). 
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Sgp130Fc protein, which is produced from sgp130Fc transgenic mice, is able to bind and 
precipitate recombinant Hyper-IL-6 indicating that the transgenic protein is functionally 
active. Incubation of wildtype serum, in which no sgp130Fc is present, with recombinant 
Hyper-IL-6 yielded no signal in the Western blot. 
 
Figure 31: Hyper-IL-6 co-precipitates with the sgp130Fc, that is present in the serum of sgp130Fc 
transgenic mice. Hyper-IL-6 was detected by Western blotting against sIL-6R. Two 
homozygous animals of the line opt3 and one wildtype animal are shown. Three different 
concentrations of recombinant Hyper-IL-6 were included as positive controls.   
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3.2.7.2 Induced acute phase response is suppressed in sgp130Fc 
transgenic animals 
 
To test if the amounts of sgp130Fc produced from transgenic animals of the “second 
generation” were sufficient to inhibit murine IL-6-transsignaling, mice were again challenged 
with Hyper-IL-6. To this end wildtype and sgp130Fc transgenic mice were injected 
intraperitoneally with 500 ng recombinant Hyper-IL-6. After four hours mice were sacrificed 
and total liver RNA was isolated. Expression of the major acute phase protein SAA2 was 
assessed by Northern blotting (Fig. 32). 
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Strong SAA2 expression was observed in wildtype animals upon injection of 500 ng Hyper-
IL-6. On the contrary, in sgp130Fc transgenic animals the mRNA expression of SAA2 was 
clearly diminished upon cytokine challenge indicating that in transgenic mice of the “second 
generation” the amounts of sgp130Fc protein were sufficient to inhibit an induced acute phase 
response. This is in contrast to the results obtained from transgenic mice of the “first 
generation”, which apparently did not express enough sgp130Fc protein to exhibit an efficient 
inhibition. In addition, this experiment clearly demonstrates that the transgenic sgp130Fc was 
functionally active.  
 
Figure 32: Northern blot showing the expression of the major acute phase protein SAA2 in the liver of 
three wildtype and four homozygous sgp130Fc transgenic mice 4 h after i.p. injection of 500 
ng Hyper-IL-6. 5 µg total liver RNA were seperated on a 1% formaldehyde containing 
agarose gel and probed with a 32P-labeled PCR fragment of the mouse SAA2 gene. 
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3.3 Air pouch model of acute inflammation 
 
Subcutaneous injection of sterile air under the dorsal skin of mice results in the formation of 
an air pouch with a lining morphologically and functionally similar to the synovium. The non-
inflamed cavity is lined by a thin layer of fibroblasts and macrophage-like cells. The 
introduction of an irritant into the cavity induces a local inflammatory response that resembles 
that seen in the rheumatoid joint (29, 107). Carrageenan, which was used in this work as the 
inflammatory stimulus, is a sulphated polysaccharide obtained from the alga Chondrus 
crispus. It has been widely used experimentally for its ability to induce an acute inflammatory 
response (24).  
Since several recent studies have implicated sIL-6R mediated signaling in the accumulation of 
leukocytes at sites of infection/inflammation (49, 96, 116), the murine air pouch model was 
employed to investigate the consequences of permanent inhibition of IL-6-transsignaling in 
sgp130Fc transgenice mice during an acute inflammatory episode.        
 
 
3.3.1 IL-6 and sIL-6R levels in the inflamed air pouch 
 
1% Carrageenan solution was administered into 6-day-old air pouches of 8-10 week old male 
C57BL/6 wildtype mice to induce an acute inflammatory response (Fig. 33). The same 
volume of sterile PBS was injected into the air pouches of other C57BL/6 animals as a 
negative control (non-inflamed air pouch).  
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Figure 33:    Schematic representation of the air pouch time schedule. At different time points after 
Carrageenan challenge the pouch was washed with 3 ml PBS and the exudate was analyzed 
by FACS (differential cell counts) or ELISA (cytokines/soluble cytokine receptors). 
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Levels of murine IL-6 and murine sIL-6R were assessed in the exudate fluid over a time 
period of three days using sandwich ELISA (Fig. 34). 
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Figure 34: Levels of endogenous IL-6 (A) and sIL-6R (B) in inflamed (1% Carrageenan) and non-
inflamed (PBS) air pouches at different time points postchallenge as measured by ELISA. 4-7 
mice per time point. In non-inflamed air pouches IL-6 and sIL-6R were hardly detectable. 
Data are represented as mean values ± SD (**= p < 0.01). 
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IL-6 levels peaked early (4 h) and declined rapidly to about 1000 pg/pouch (48 h and 72 h). 
On the contrary, sIL-6R levels plateaued at early time points (∼ 1 ng/pouch) and then 
increased to approximately 3 ng/pouch within 3 days upon induction of inflammation. 
Together, these results point at a role for IL-6 in the early stage of inflammation, whereas sIL-
6R appears to be important rather at later stages. In non-inflamed air pouches IL-6 as well as 
sIL-6R were below the detection limit. 
 
 
3.3.2 Levels of transgenic sgp130Fc in the inflamed air pouch 
 
As mentioned above, for an efficient inhibition of IL-6 transsignaling a molar excess of 
sgp130 is essential. When using the air pouch model, it is important that sufficient amounts of 
sgp130Fc protein are present at sites of inflammation. Therefore, levels of sgp130Fc in 
inflamed air pouches of sgp130Fc transgenic animals were determined by ELISA.  
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The level of endogenous sIL-6R in wildtype animals 72 h upon induction of inflammation 
was about 3 ng/pouch (Fig. 34B), whereas the concentration of sgp130Fc in the inflamed air 
  
Figure 35: Levels of transgenic sgp130Fc in inflamed air pouches of sgp130Fc transgenic mice. 1% 
Carrageenan was injected in 6-day-old air pouches and 72 h upon stimulation the levels of 
sgp130Fc were assessed by ELISA. Each bar represents one sgp130Fc transgenic animal. 
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pouch of transgenic animals was 2.8 ± 0.9 µg/pouch (Fig. 35). Therefore, an approximately 
250-fold molar excess of sgp130Fc was present in the air pouches. As a 10-fold molar excess 
of sgp130Fc is sufficient to block IL-6/sIL-6R responses in vitro (55), the sgp130Fc levels in 
inflamed air pouches of sgp130Fc transgenic mice should be high enough to effectively 
inhibit endogenous IL-6-transsignaling. 
 
 
3.3.3 Impaired leukocyte recruitment during acute 
inflammation in sgp130Fc transgenic mice 
 
During acute inflammation, leukocytes (mainly PMNs and monocytes/macrophages, at later 
stages T and B lymphocytes) migrate from blood vessels into the inflamed tissue (in this case 
the air pouch). Inflammation was induced by injection of 1% Carrageenan into the air 
pouches of 8-10 weeks old male sgp130Fc transgenic mice and genetically matched wildtype 
littermates. Infiltrating cells were counted and then analyzed by Flow Cytometry, using 
fluorescence-conjugated antibodies specific for neutrophil granulocytes, macrophages, T and 
B cells.  
2
4
6
8
10
12
14
4 h 12 h 72 h
in
fil
tr
at
in
g 
ce
lls
 
x
 
10
6 
/ p
o
u
ch
WT
sgp130Fc tg
**
A
2
4
6
8
10
12
14
16
18
in
fil
tr
at
in
g 
ce
lls
 
x
 
10
6 
/ p
o
u
ch
24 h
WT
IL-6 -/-
**
B
 
 
 
 
 
 
Figure 36: (A) Quantitative Flow Cytometry analysis showing inflammatory cells infiltrating the air pouch 4 h, 12 h 
and 72 h after injection of 1% Carrageenan. Comparison of homozygous sgp130Fc transgenic and 
wildtype animals (WT). 4-7 mice per group. Data are represented as mean values ± SD (**= p < 0.01). 
(B) Total leukocytes infiltrating the air pouch 24 h after 1% Carrageenan challenge. Comparison of IL-6-
knock out (IL-6-/-) and wildtype mice. Cells were counted after staining with erythrosine. 5-17 mice per 
group. Data taken from (96).   
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Three time points (4 h, 12 h and 72 h) were investigated. The numbers of total cells 
infiltrating the air pouch were roughly the same 4 h and 12 h after induction of inflammation 
(about 3 – 3.5 x 106 infiltrating cells/pouch). Furthermore, no major differences in the number 
of infiltrating cells between sgp130Fc transgenic and wildtype animals were observed for the 
two early time points. When analyzing the 72 h time point, it turned out that the number of 
total infiltrating cells was significantly reduced in sgp130Fc transgenic mice as compared to 
wildtyp mice. Whereas the cell number in wildtype animals increased to 10.9 x 106/pouch, the 
inflammatory reaction in the sgp130Fc transgenic mice was markedly suppressed, as no 
considerable increase in total cell number could be detected (compared to the 4 h and 12 h 
time points) (Fig. 36A). This is consistent with the work of Romano et al. (96), who used the 
same air pouch model and showed that in IL-6-deficient mice leukocyte accumulation was 
significantly impaired (Fig. 36B). In this respect, the results obtained with sgp130Fc 
transgenic animals revealed that impaired leukocyte accumulation during acute inflammation 
was only due to IL-6-transsignaling, and not classical IL-6-signaling. 
It has been previously shown that the response to Carrageenan is a classical acute 
inflammation dominated by neutrophil granulocytes (or neutrophils) followed by a 
mononuclear phase (22). The numbers of both neutrophils and macrophages were assessed by 
Flow Cytometry at 4 h, 12 h and 72 h after Carrageenan injection in sgp130Fc transgenic and 
wildtype mice (Fig. 37). 
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In agreement with previous reports, in wildtype mice neutrophils were the dominating cell 
type in the inflammatory infiltrates at the early time points (4 h and 12 h). However, during a 
later stage of inflammation (72 h) macrophages were the predominant leukocyte 
subpopulation with cell numbers reaching 4 x 106/pouch (> 40% of total cells). 
In sgp130Fc transgenic mice the proportion of neutrophils in the air pouch was initially 
comparable with wildtype animals, but then drastically decreased at later time points, whereas 
the number of neutrophils in wildtype animals peaked at 12 h and slightly declined 72 h after 
induction of inflammation (Fig. 37A). In terms of infiltrating macrophages no significant 
differences were observed between sgp130Fc transgenic mice and wildtype animals during 
the onset of inflammation (4 h and 12 h), with the proportion of macrophages being 
comparatively low in both groups. In contrast, 72 h upon Carrageenan injection the number of 
macrophages was strongly reduced in sgp130Fc transgenic mice suggesting that inhibition of 
IL-6-transsignaling led to impaired macrophage recruitment in these animals (Fig. 37B).    
Figure 37: Neutrophils (A) and macrophages (B) infiltrating the air pouch 4 h, 12 h and 72 h after 
injection of 1% Carrageenan as measured by Flow Cytometry. 4-7 mice per group. Data are 
represented as mean values ± SD (**= p < 0.01, *= p < 0.05). 
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The number of total cells migrated in response to PBS alone was similarly low in sgp130Fc 
transgenic and wildtype animals at 72 h (< 0.9 x 106/pouch, not presented). No T or B cells 
were detected in the inflamed air pouch throughout the course of this experiment.  
 
 
3.3.4 Reduced levels of the CC chemokine MCP-1 during 
acute inflammation in sgp130Fc transgenic mice 
 
Numerous in vitro studies have shown that resident cells (such as fibroblasts, smooth muscle 
cells and epithelial cells) as well as infiltrating leukocytes are involved in the evolution of the 
inflammatory response (11). Both cell types may synthesize CXC or CC chemokines after 
stimulation by proinflammatory cytokines, which in turn recruit granulocytes or 
monocytes/macrophages to the site of inflammtion, respectively. In the murine air pouch 
model the exudates, which were generated after injection of an inflammatory stimulus, can be 
easily collected and further analyzed. In this study we focussed on the CXC chemokine KC, 
which is the murine homologue of human Groα, and the CC chemokine monocyte 
chemoattractant protein-1 (MCP-1). KC mediates the recruitment of neutrophils, while MCP-
1 directs monocytes/macrophages to the inflammatory site (49). The amounts of both 
chemokines in the inflamed air pouches of sgp130Fc transgenic and wildtype mice were 
measured using sandwich ELISA (Fig. 38). 
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In wildtype animals KC levels peaked at 4 h after induction of inflammation and rapidly 
decreased during the later stages of inflammation. Conversely, the amounts of MCP-1 were 
moderately increasing during the onset of inflammation, whereas the highest levels were 
measured 72 h after induction of inflammation. These results reflect the fact that neutrophils 
were the first cells to enter the site of an inflammation, which were later to be replaced by 
monocytes/macrophages.  
With respect to the KC levels sgp130Fc transgenic mice showed no significant difference 
compared to wildtype animals, although the amounts of KC in the transgenic animals were 
slightly reduced 4 h and 72 h after induction of inflammation. By contrast, a clear difference 
could be observed regarding the levels of MCP-1 in the inflamed air pouch. Whereas the 
amounts of MCP-1 in wildtype animals steadily increased and peaked at 72 h upon injection 
of Carrageenan, the MCP-1 levels in sgp130Fc transgenic animals were slightly lower at 4 h 
and then plateaued during the course of inflammation. These results clearly show that the 
observed deficit in macrophage recruitment is due to reduced MCP-1 levels, since MCP-1 is 
the most important chemokine involved in the attraction of macrophages. Additionally, this is 
Figure 38: Levels of endogenous KC (A) and MCP-1 (B) in inflamed air pouches of sgp130Fc transgenic 
and wildtype mice 4 h, 12 h and 72 h following Carrageenan challenge. KC and MCP-1 
concentrations were determined by ELISA. 4-7 mice per group. Data are represented as mean 
values ± SD (**= p < 0.01). 
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consistent with the work of Romano et al. (96), who showed that in IL-6-deficient mice both 
leukocyte accumulation and MCP-1 production were impaired.  
 
 
3.3.5 Soluble IL-6R is released from infiltrating neutrophils 
(neutrophil depletion) 
 
The cellular source of sIL-6R in the air pouch model as well as in any other inflammation 
model is not known. Since the lining cells of the air pouch are very unlikely to express IL-6R 
(96) and a positive correlation between infiltrating leukocytes and the amount of sIL-6R was 
found in a murine peritonitis model (49), it is therefore tempting to speculate that either 
infiltrating neutrophils or macrophages release their membrane-bound IL-6R upon migration 
into the inflamed tissue.  
Mice injected i.p. with purified Ly6GC mAB, which recognize a surface marker on mature 
murine granulocytes (Gr-1), experienced a profound depletion of neutrophils in the 
bloodstream and the air pouch (20, 36). To generate neutropenic animals, 8-10 weeks old 
male C57BL/6 wildtype mice were challenged i.p. with 100 µg of Ly6GC mAB 18 h before 
injection of 1% Carrageenan. Cell numbers of neutrophils and macrophages were determined 
by Flow Cytometry, while levels of sIL-6R were assessed by ELISA in the inflamed air 
pouches 24 h and 72 h after induction of inflammation.  
As already seen in the FSC/SSC plot (Fig. 39A), a distinct population of neutrophils emerged 
24 h after Carrageenan injection, which disappeared when the animals were treated with the 
depleting antibody before Carrageenan challenge. The quantitative Flow Cytometry analysis, 
shown in Fig. 39B, revealed that 24 h after induction of inflammation no neutrophils were 
present in the inflamed air pouch of neutropenic animals. 72 h after Carrageenan injection 
neutrophils were hardly detectable. These results indicate that in inflamed wildtype mice 
neutrophil depletion was succesful. 
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With respect to the levels of sIL-6R no difference was observed in the inflamed air pouches of 
PBS treated and neutropenic animals 24 h after Carrageenan injection. In contrast, 72 h after 
Figure 39: Flow Cytometry analysis showing that in inflamed air pouches of C57BL/6 wildtype mice 
neutrophil depletion was successful. 18 h before injection of Carrageenan animals were 
administered i.p. with 100 µg of a neutrophil depleting mAB (Ly6GC) or PBS. (A) FSC/SSC 
plot. 24 h after induction of inflammation a distinct neutrophil population was visible in PBS 
treated mice (left), which dissapeared in neutropenic animals (right). (B) Quantitative Flow 
Cytometry analysis revealed that neutrophils were hardly detectable in inflamed air pouches 
24 h and 72 h upon induction of inflammation. 4 mice per group. Data are represented as 
mean values ± SD (*= p < 0.05). 
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induction of inflammation a strong increase in the amount of sIL-6R was noticed in PBS 
treated mice, whereas in neutropenic mice no appreciable increase was found (Fig. 40). These 
results clearly show, that sIL-6R was released from neutrophils, that migrated into the 
inflamed air pouch. 
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The proportion of macrophages in the inflamed air pouches of control and neutropenic 
animals 24 h after injection of Carrageenan was not modified (Fig. 41). However, a drastic 
decrease in macrophage numbers was observed in neutropenic animals compared to control 
mice after 72 h of treatment, suggesting a neutrophil derived factor being implicated in 
macrophage recruitment during the later stages of inflammation.    
 
 
 
Figure 40: sIL-6R was released from infiltrating neutrophils. Levels of sIL-6R were determined by ELISA 
24 h and 72 h after injection of Carrageenan in PBS and Ly6GC mAB treated C57BL/6 wildtype 
mice. 4 mice per group. Data are represented as mean values ± SD (*= p < 0.05). 
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Figure 41: Macrophage recruitment was impaired in neutropenic mice. Quantitative Flow Cytometry 
analysis showing the number of macrophages 24 h and 72 h after injection of Carrageenan in 
PBS and Ly6GC mAB treated C57BL/6 wildtype mice. 4 mice per group. Data are 
represented as mean values ± SD (*= p < 0.05). 
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4  Discussion 
 
 
4.1  Generation of sgp130Fc transgenic mice 
 
Sgp130 is the natural inhibitor of IL-6-transsignaling and selectively blocks IL-6 responses 
mediated by the sIL-6R, whereas IL-6 responses via the membrane-bound IL-6R remain 
unaffected. Soluble IL6-R mediated signaling has been implicated in many 
pathophysiological conditions including rheumatoid athritis (85), peritonitis (49), colon 
cancer (7) and inflammatory bowel disease (4). Administration of recombinant sgp130Fc in 
animal models of the latter diseases has proven effective to ameliorate the clinical score in the 
respective murine disease models. 
In order to examine the pathophysiological role of sIL-6R mediated responses in vivo, 
transgenic mice were generated in this project, which overexpress human sgp130Fc from a 
liver-specific promoter. In this respect it is impotant to consider the species specificity of sIL-
6R and the other components of the IL-6 receptor system (Fig. 42). It is long known that there 
is a strict species specificity for the interaction between IL-6 and the IL-6R. Human IL-6 
binds to both, human and mouse IL-6R, whereas murine IL-6 only binds to the murine 
receptor (118). In contrast, murine sIL-6R is able to associate with murine and human IL-6 as 
well as murine and human sgp130 (55). Endogenous IL-6-transsignaling responses in mice, 
which involve both murine IL-6 and murine sIL-6R, can therefore be inhibited by human 
sgp130. 
 
mIL-6 hIL-6
mIL-6R hIL-6R
mgp130 hgp130
 
 
Figure 42: Species specificity within the 
IL-6-receptor-system. Human 
IL-6 (hIL-6) can bind both 
human (hIL-6R) and murine 
IL-6R (mIL-6R), whereas 
murine IL-6 (mIL-6) only binds 
murine IL-6R. The murine IL-
6R, like human IL-6R, can 
associate with both human 
(hgp130) and murine gp130 
(mgp130). 
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Sgp130Fc is a fusion protein consisting of the extracellular portion of gp130 connected to the 
constant region of a human IgG1 heavy chain (Fc part). When considering its inhibitory 
capacity the dimerized sgp130Fc turned out to be about 10-fold more active than monomeric 
sgp130, which is most likely due to the chimeric character of sgp130Fc. By employing co-
precipiation experiments and fluorescence resonance energy transfer (FRET) it was recently 
shown that on the living cell gp130 exists as a preformed dimer in the plasma membrane. 
Addition of ligand further enhances the dimer formation presumably through changes in the 
spatial orientation of the receptor chains, which in turn leads to receptor activation and 
triggering of intracellular signaling cascades (40, 115). The availability of a preformed gp130 
dimer accelerates the receptor complex assembly, since two gp130 monomers do not need to 
find each other on the plasma membrane to form a signaling competent receptor complex. 
Therefore, sgp130Fc reflects the situation on the living cell, which is most likely the reason 
for the higher activity of sgp130Fc compared to the monomeric protein.  
Taking into account both the dimeric character of sgp130Fc and the binding promiscuity of 
murine sIL-6R towards IL-6 and sgp130, transgenic mice expressing human sgp130Fc are an 
ideal model system to analyze the consequences of murine IL-6-transsignaling and represent 
an “IL-6-transsignaling knockout” in mice.  
In general, blocking of sIL-6R mediated responses requires a molar excess of sgp130, since 
sgp130 has to compete with the surface expressed counterpart for the IL-6/sIL-6R complex 
(55). Hence, when considering the inhibition of IL-6-transsignaling in mice, it is mandatory 
that transgenic sgp130 is present in sufficient amounts to effectively block the complex of 
murine IL-6 and sIL-6R.  
In this project, transgenic mice were generated, which express human sgp130Fc under the 
transcriptional control of the PEPCK promoter. This promoter is mainly active in liver and 
kidney (5, 70). Since the liver exhibits a high synthetic capacity and the PEPCK promoter is 
considered to be comparatively strong, transgenic proteins expressed under the PEPCK 
promoter have been shown to accumulate in high amounts in the circulation with serum levels 
of the transgene being in the low microgram range (70, 122). For instance, sIL-6R transgenic 
and IL-6/sIL-6R double transgenic mice show serum concentrations of 4-8 µg sIL-6R/ml 
serum (89, 106). In contrast, sgp130Fc transgenic mice of the “first generation” showed 
transgene serum levels of ≤ 0.55 µg/ml (see Fig. 18), which is far below the transgene serum 
concentration observed for sIL-6R transgenic mice. There are several reasons, which could 
contribute to this comparably low expression of sgp130Fc. For example, gene silencing 
effects have been observed when the transgene integrated into heterochromatic regions of the 
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mouse genome such as the centromere or telomere or their borders (27, 30, 71). But since all 
four independent transgenic lines (L1, L3, L4 and L6) showed similar weak transgene 
expression, this explanation is rather unlikely, even though the exact transgene integration 
sites have not been determined. It has also been reported that the presence of multiple copies 
of a transgene within a concatameric array can have a repressive effect upon gene expression 
in mammalian systems (repeat-induced gene silencing), with a reduction in copy number 
resulting in a marked increase in expression of the transgene (37, 69). Furthermore, DNA 
methylation of CpG-rich sequences may lead to reduced transgene expression (15).  
Phosphoenolpyruvate-carboxykinase (PEPCK) is the key regulatory enzyme of hepatic 
gluconeogenesis and feeding the animals a carbohydrate low diet resulted in stimulation of 
the PEPCK promoter, which controlled sgp130Fc expression at the transcriptional level (70). 
Nevertheless, serum concentrations of sgp130Fc could not substantially be elevated 
(sgp130Fc levels were estimated to be in the range of 1-2 µg/ml serum after the carbohydrate 
low diet) and the relatively low sgp130Fc serum levels in the first transgenic mice failed to 
inhibit the Hyper-IL-6-induced acute phase response. Therefore, a new generation of 
transgenic animals was generated, which express sgp130Fc from a codon-optimized cDNA. 
Codon-optimization of a defined cDNA leads to increased mRNA stability and enhanced 
translational efficiency. In addition, the optimized sgp130Fc cDNA was inserted behind the 
2nd β-globin intron into the expression vector, whereas the protein coding region in the 
original sgp130Fc transgenic mice was located in front of the intron. It has been previously 
reported that the position of the heterologous intron within the expression vector can be 
crucial for effective transgene expression (86). Indeed, a more than 50-fold increase in the 
sgp130Fc serum concentration was observed in homozygous animals of the “second 
generation” when compared to homozygous animals of the “first generation” of sgp130Fc 
transgenic mice (0.55  34.3 µg/ml serum). Transfection experiments in HepG2 cells 
revealed that both cDNA optimization and the effect of the intron position contributed to the 
enhanced transgene expression. Interestingly, neither cDNA optimization nor the change of 
the intron position alone resulted in an appreciable increase in transgene expression with 
sgp130Fc being hardly detectable in the corresponding HepG2 cell supernatants (Fig. 25). 
To prove that the sgp130Fc protein produced from transgenic mice is active, two different 
approaches were taken. In the first experiment serum from transgenic mice was mixed with 
Hyper-IL-6, a fusion protein of IL-6 and the ligand binding domain of IL-6R (31). It has been 
previously shown that recombinant sgp130Fc is able to bind Hyper-IL-6 and to inhibit Hyper-
IL-6 mediated proliferation of gp130 expressing hematopoietic progenitor cells (55). It clearly 
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turned out that sgp130Fc, derived from the serum of transgenic mice, can precipitate 
recombinant Hyper-IL-6 indicating that the transgenic protein is active. 
The acute phase response, which is elicited a short time after injuries or the onset of 
infections, is characterized by the coordinated synthesis of so-called acute phase proteins 
(APPs) by hepatocytes in the liver (101). Serum amyloid A (SAA) is one of the major APPs 
in mice and it is upregulated up to 1,000-fold in response to various stimuli, among them 
bacterial lipopolysaccharides and cytokines such as IL-1, IL-6 and TNFα (1).  
Whereas gp130 tissue expression is ubiquitous, the IL-6R is expressed only on a few cell 
types, including hepatocytes and some leukocyte subpopulations (T and B lymphocytes, 
neutrophils, monocytes/macrophages). The number of gp130 molecules on the cell surface is 
believed to be relatively constant, while the amount of IL-6R differs from one cell type to 
another. Hepatocytes express fewer IL-6R molecules on their surface than gp130 and can 
respond to IL-6 alone, but this response can be enhanced by the addition of the sIL-6R (90). 
Injection of Hyper-IL-6 into the peritoneal cavity of wildtype mice therefore led to a 
prolonged acute phase response. In addition, the acute phase reaction reaction turned out to be 
more pronounced as compared to IL-6 (88), which is due to the fact that 10 times more gp130 
than IL-6R molecules are located on the hepatocyte surface (90). As assessed by Northern 
blotting of SAA mRNA, in sgp130Fc transgenic mice of the “second generation” the acute 
phase response was significantly reduced upon intraperitoneal injection of Hyper-IL-6 when 
compared to wildtype animals (Fig. 32). This result first demonstrates, together with the 
Hyper-IL-6 immunoprecipitation experiment, that transgenic sgp130Fc is functionally active. 
In addition, the experiment shows that the amounts of sgp130Fc in the “second generation” of 
transgenic mice were sufficient to suppress the acute phase response induced by Hyper-IL-6. 
This is in contrast to the first sgp130Fc mice, which did not produce enough sgp130Fc to 
inhibit the Hyper-IL-6-induced acute phase. 
As mentioned above, the PEPCK promoter, which drives the expression of sgp130Fc in the 
transgenic animals, has been shown to be mainly active in liver and kidney (63, 70). 
Consistently, in sgp130Fc transgenic animals a strong expression of sgp130Fc was observed 
in liver and kidney. However, appreciable amounts of sgp130Fc mRNA were also found in 
lung and muscle, which is in contrast to some previous reports (43, 70). 
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4.2  Role of sIL-6R during acute inflammation  
(air pouch model) 
 
Inflammation is the response of living tissue to damage, microbial infections or other 
immunologic stimulation. The local inflammatory reaction is characterized by an increased 
blood supply to the tissue ''in danger'' and enhanced vascular permeability with white blood 
cells migrating out of the capillaries into the inflamed tissue. The increased capillary 
permeability is thereby provoked by retraction of the endothelial cells. In the earliest stages of 
inflammation neutrophils are particularly prevalent, at later stages monocytes, macrophages 
and lymphocytes (specific subsets of T-cells and B-cells) appear at the site of injury/infection. 
Neutrophils and macrophages mount a rapid, non-specific phagocytic response by taking up 
bacteria and cellular debris, whereas lymphocytes are associated with antigen-specific and 
more tightly regulated immune responses. The highly efficient process of cellular influx to 
inflammatory sites is mediated by cytokines, chemokines, products of the plasma enzyme 
systems (complement, the coagulation clothing, kinin and fibrinolytic pathways), lipid 
mediators (prostaglandins and leukotrienes) released from different cells, and by vasoactive 
substances secreted from mast cells, basophils and platelets. When leukocytes have arrived at 
an infected area, they release mediators which control the later accumulation and activation of 
other cells (50). The major proinflammatory cytokines, which are responsible for early 
responses, are IL-1, TNFα and IL-6. Most of them are released from tissue-resident 
macrophages and activate endothelial cells to upregulate the receptors VCAM-1, ICAM-1, E-
selectin, and L-selectin for various immune cells and to produce an array of chemokines that 
chemoattract inflammatory cells (3, 46). Cleavage and activation of IL-1β by so-called 
inflammatory caspases (i.e. caspase-1 and caspase-5) proceeds in a large multiprotein 
complex that has been termed inflammasome (92). 
There are several lines of evidence that sIL-6R signaling is involved in the control of 
leukocyte recruitment during inflammation (73, 96). In particular, it has been proposed that 
the transition from the initial neutrophilic stage to the more sustained influx of mononuclear 
leukocytes strongly relies on the presence of IL-6 and the soluble IL-6R (Fig. 43). Thereby 
soluble IL-6R is most likely released from infiltrating neutrophils, since sIL-6R 
concentrations in early inflammatory exudates strongly correlate with leukocyte numbers. 
Combined IL-6 and sIL-6R then triggers endothelial/mesothelial cells to synthesize the 
chemokines MCP-1 and MCP-3, which attract monocytes and macrophages, whereas 
secretion of IL-8 and GROα is concurrently suppressed. The latter chemokines mediate the 
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recruitment of neutrophils to the site of inflammation. Mesothelial as well as endothelial cells 
do not express the cognate IL-6R, which infers that these cells are unresponsive to IL-6 itself 
and therefore necessitate additional sIL-6R for signal transduction (49, 96). 
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In previous animal studies dealing with the impact of IL-6-transsignaling on inflammation 
either IL-6 knock-out mice were employed, in which sIL-6R mediated signaling was restored 
by administration of recombinant Hyper-IL-6 (alternatively IL-6 in combination with sIL-
6R), or wildtype mice were challenged with doses of recombinant sgp130Fc to selectively 
block sIL-6R responses. Since the sgp130Fc transgenic mice, which were generated in this 
work, permanently produce high levels of endogenous sgp130Fc, these animals are an elegant 
tool to effectively inhibit IL-6-transsignaling in vivo. Especially, sgp130Fc transgenic mice 
represent the ideal model system to investigate the influence of sIL-6R on the development of 
chronic inflammatory diseases, such as rheumatoid arthritis or inflammation-induced colon 
cancer, which would require the presence of sgp130 over long periods.    
In this work the murine air pouch model was used to investigate the role of sIL-6R signaling 
in the evolution of an acute inflammatory response. Injection of Carrageenan into dorsal air 
pouches of mice resulted in a local inflammatory reaction, which has been monitored over a 
Figure 43: IL-6-transsignaling differentially regulates the switch between the initial neutrophilic stage 
of inflammation and the later, more sustained influx of mononuclear cells. 
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time period of 3 days. In the initial phase of inflammation (4 h and 12 h after induction) high 
levels of IL-6 were measured in the pouch exudate, which declined thereafter, whereas 
considerable amounts of sIL-6R were found only at later time points (48 h and 72 h, Fig. 34). 
This leads to the suggestion that IL-6 plays an important role in the early onset of 
inflammation, while sIL-6R mediated signaling is involved rather at a later stage of an 
inflammatory insult.  
The air pouch is a highly vascularized compartment and contains copious vessels with 
features of high endothelial venules (21, 96). Endothelial cells play an important, active role 
in inflammatory processes and secrete high amounts of IL-6 in response to proinflammatory 
signals, including microbial products, IL-1 and TNFα (51, 93, 108). As noted previously, 
endothelial cells lack membrane-bound IL-6R and therefore do not respond to IL-6 alone. 
Since endothelial cells express gp130, the presence of sIL-6R would render them responsive 
to IL-6. Given that a molar excess of sgp130 is needed to succesfully disturb sIL-6R 
activities, it is of importance that sufficient amounts of sgp130Fc are available in the air 
pouch. A molar excess of approximately 250-fold could be detected in the pouch fluid when 
comparing transgenic sgp130Fc and endogenous sIL-6R levels (Fig. 35). It has been shown in 
vitro that a 10-fold excess of sgp130Fc is enough to block sIL-6R mediated cell proliferation. 
Therefore the sgp130Fc/sIL-6R ratio found in inflamed air pouches of sgp130Fc transgenic 
mice was sufficient to inhibit murine IL-6-transsignaling.  
During the onset of inflammation, the Carrageenan induced response was dominated by 
neutrophils, which infiltrated the air pouch as early as 4 h after injection, followed by a 
delayed mononuclear phase (Fig. 37). When considering the number of total cells infiltrating 
the air pouch, it turned out that the overall inflammatory reaction was strongly reduced in 
sgp130Fc transgenic mice, since cell numbers did not considerably increase during 
development of inflammation as compared to wildtype animals (Fig. 36). Neutrophil numbers 
in sgp130Fc transgenic animals were similar to wildtype mice 4 h after induction of 
inflammation, but strongly decreased during later stages of inflammation, whereas neutrophils 
in wildtype animals only moderately declined. Macrophage numbers were roughly the same 
in sgp130Fc transgenic and wildtype mice 4 h and 12 h after stimulation. In wildtype animals 
a substantial rise of mononuclear cells was observed 72 h after induction, while in the 
presence of transgenic sgp130Fc macrophage numbers remained constant during the course of 
inflammation (Fig. 37). At the chemokine level the reduced accumulation of 
monocytes/macrophages in sgp130Fc transgenic mice was paralleled by a diminished 
secretion of MCP-1 into the pouch (Fig. 38). This is in agreement with the work of Romano et 
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al. (96), who also employed the murine air pouch model of acute inflammation showing that 
in IL-6 knockout mice both leukocyte recruitment and MCP-1 secretion was significantly 
reduced. It has also been shown that at the cellular level the stimulation of mesothelial and 
endothelial cells with the IL-6/sIL-6R complex resulted in a strong upregulation of MCP-1. 
Furthermore, i.p. administration of Hyper-IL-6 in a murine peritonitis model led to an 
enhanced MCP-1 response (49, 56, 96). Although neutrophil numbers in sgp130Fc transgenic 
mice were strongly reduced during later stages of inflammation, the KC levels measured in 
the inflamed air pouches of the transgenic animals did not significantly differ from those 
found in wildtype mice, suggesting that in this disease model probably other CXC 
chemokines, such as MIP-2 (the murine homologue of IL-8), were involved in neutrophil 
recruitment (Fig. 38). Taken together, these results indicate an important role for the IL-6/sIL-
6R complex in mediating the switch from the initial neutrophilic to the later mononuclear 
phase of inflammation, since in sgp130Fc transgenic mice both the accumulation of 
macrophages and neutrophils was impaired only at later stages in the development of 
inflammation (which was additionally confirmed by the reduced MCP-1 levels). In contrast, 
the initial influx of neutrophils, which is commonly regarded as the first step of an 
inflammatory response, was not affected by sgp130Fc. 
The cellular source of sIL-6R in acute as well as chronic inflammatory conditions is not 
known yet. Endothelial cells, which are probably the most important cells in the evolution of 
inflammation as they secrete the chemokines that in turn attract the respective inflammatory 
cells, do not express cognate IL-6R. However, there is strong evidence that infiltrating 
leukocytes, such as neutrophils and macrophages, substantially contribute to the levels of sIL-
6R found in inflammatory exudates. For instance, in rheumathoid arthritis patients a strong 
correlation exists between the degree of leukocyte infiltration into an arthritic joint and 
elevated synovial sIL-6R concentrations (23). A similar correlation is observed in early 
inflammatory exudates of a murine peritonitis model, where increased leukocyte numbers 
have been associated with elevated sIL-6R levels. Since infiltrating cells at such early stages 
of inflammation mainly consist of neutrophils, it has been concluded that neutrophils are most 
likely the main source of released sIL-6R (49). However, direct evidence is still missing that 
the sIL-6R is liberated from infiltrating neutrophils. In the present work neutropenic mice 
were generated by i.p. injection of a neutrophil depleting antibody with no neutrophils being 
detectable in the inflamed air pouch 24 h as well as 72 h following Carrageenan injection. 
While sIL-6R levels in untreated animals significantly increased 72 h after stimulation, no rise 
of sIL-6R was observed in neutropenic mice clearly indicating that during acute inflammation 
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sIL-6R was released from migrating neutrophils (Fig. 40). In addition, macrophage 
recruitment was impaired in neutropenic animals to a similar extent as seen in sgp130Fc 
transgenic mice suggesting that sIL-6R is the critical neutrophil-associated factor implicated 
in macrophage accumulation during later stages of inflammation (Fig. 41).  
 
IL-6
infection
IL-1β, TNFα
IL-8, GROα
1. 2.
3.
IL-6
sIL-6R
MCP-1
neutrophils macrophages air pouch lining tissue
blood vessel
 
 
 
 
 
 
 
 
 
 
This is consistent with previous studies showing that sIL-6R is shed from neutrophils 
following stimulation with f-Met-Leu-Phe, C-reactive protein and IL-8 as well as GROα (49, 
Figure 44: Infection/inflammation stimulates tissue-resident macrophages to secrete the proinflammatory 
cytokines TNFα and IL-1β, which in turn induce CXC chemokine and IL-6 secretion from 
endothelial cells (1). Endothelial cells do not express membrane-bound IL-6R and are therefore not 
responsive towards IL-6 itself. Infiltrating neutrophils shed their IL-6R upon apoptosis and the IL-
6/sIL-6R complex stimulates endothelial cells to produce the CC chemokine MCP-1 (2), which 
subsequently attracts macrophages to the site of inflammation. The replacement of neutrophils by 
mononuclear cells (3) is an important intermediate step in the resolution of inflammation, which is  
controlled by the presence of sIL-6R. 
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53, 73). Very recent data obtained in our laboratory reveal that sIL-6R is shed from apoptotic 
neutrophils by the metalloprotease ADAM17 (13). 
Based on the results presented in this work (utilizing sgp130Fc transgenic and neutropenic 
mice in an air pouch model of acute inflammation) combined with the data observed with 
apoptotic neutrophils we propose the following model regarding the role of sIL-6R during 
inflammation (Fig. 44): The first step in an inflammatory reaction is the release of the pro-
inflammatory cytokines IL-1β, TNFα and IL-6. Endothelial cells do not express IL-6R and 
are therefore not responsive to IL-6 but are responsive to IL-1β and TNFα. Activation of 
endothelial cells leads to the secretion of CXC chemokines and subsequently to the attraction 
of neutrophils. Apoptotic neutrophils then shed their membrane-expressed IL-6R and the 
complex of IL-6 and sIL-6R stimulates endothelial cells to produce CC chemokines (i.e. 
MCP-1) leading to a substitution of neutrophils by monocytes/macrophages. Thus, the 
transition from the initial neutrophilic to the more sustained mononuclear phase of 
inflammation is controlled by the presence of sIL-6R which is shed from apoptotic 
neutrophils (Fig. 43, 44). 
 
 
4.3  Outlook 
 
In this work transgenic mice were generated, which accumulated sgp130Fc in high amounts 
in the circulation. The murine air pouch model of acute inflammation was used to initially 
characterize these animals and it could be demonstrated that sgp130Fc transgenic mice 
showed a reduced inflammatory reaction in response to Carrageenan challenge.  
Sgp130Fc transgenic mice represent an “IL-6-transsignaling knock out” model. Although 
sgp130Fc transgenic mice showed high serum levels of sgp130Fc, the animals exhibited no 
obvious phenotypic alterations. It is therefore tempting to speculate that IL-6-transsignaling 
plays no role in daily life. In contrast, it has been shown that IL-6-transsignaling is involved 
in the pathogenesis as well as the maintenance of several chronic inflammatory diseases, 
including inflammatory bowel disease (4), ileitis (72), rheumatoid arthritis (23, 85) and even 
inflammation-induced colon cancer (7).  
It would be therefore of special interest to investigate the impact of permanently high 
sgp130Fc serum levels on the onset and perpetuation of these inflammatory disorders, since in 
mice these diseases usually develop over a longer time period and would require the long-
term administration of exogenous sgp130Fc. Therefore, continous inhibition of IL-6-
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transsignaling in sgp130Fc transgenic animals will help to clarify the role of sIL-6R mediated 
signaling in the development of chronic diseases, infections and cancer.  
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5  Summary 
 
Interleukin-6 (IL-6) is a pleiotropic cytokine with various cellular functions, among them the 
induction of acute phase proteins in the liver and the stimulation of B cells. On target cells, 
IL-6 initially binds an IL-6-specific α-receptor, the IL-6R. Upon binding of the surface-
expressed IL-6R the IL-6/IL-6R complex leads to a homodimerization of gp130, the second 
subunit of the IL-6 receptor complex. A soluble form of the IL-6R (sIL-6R) can be generated 
via proteolytic cleavage or alternative splicing and the complex of IL-6 and sIL-6R is capable 
of activating cells which lack the membrane-bound IL-6R (IL-6-transsignaling). IL-6-
transsignaling can be selectively inhibited by a naturally occuring, soluble form of gp130 
(sgp130). Many inflammatory and neoplastic disorders have been attributed to sIL-6R 
mediated signaling and recombinant sgp130 is expected to be a valuable therapeutic tool to 
treat these diseases. 
In this work transgenic mice were generated, which express sgp130Fc under a liver-specific 
promoter. Sgp130Fc is a fusion protein consisting of the extracellular part of gp130 and the 
Fc part of a human IgG antibody. Transgenic mice of the “first generation” showed 
comparably low sgp130Fc serum levels (<0.55 µg/ml), which were not sufficient to inhibit 
murine IL-6-transsignaling (in terms of acute phase induction by injection of Hyper-IL-6). 
New transgenic mice were created, which express sgp130Fc from a codon-optimized cDNA. 
In the “second generation” of sgp130Fc transgenic mice a more than 50-fold increase in 
sgp130Fc serum expression was achieved (≤ 34.4 µg/ml). It was shown that transgenic 
sgp130Fc protein is functionally active and that the amounts of sgp130Fc were sufficient to 
block murine IL-6-transsignaling. Northern blot analysis revealed sgp130Fc mRNA 
expression in liver, kidney, lung and muscle. 
By employing the murine air pouch model of acute inflammation it was demonstrated that 
leukocyte accumulation in sgp130Fc transgenic mice was profoundly impaired compared to 
wildtype mice. In particular, neutrophil and macrophage infiltration was disturbed only at 
later stages of inflammation, which was paralleled by a reduced production of the CC 
chemokine MCP-1. High local levels of IL-6 were detected during the onset of inflammation, 
whereas sIL-6R peaked at later time points. By depleting the neutrophils at the site of 
inflammation it could be demonstrated that sIL-6R was released from transmigrating 
neutrophils. Taken together, these results indicate an important role for sIL-6R in mediating 
the transition between the initial, neutrophilic stage of infection and the later mononuclear cell 
influx, thereby promoting the resolution of inflammation.   
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6  Zusammenfassung 
 
Interleukin-6 (IL-6) ist ein pleiotropes Zytokin und besitzt ein breites Wirkungsspektrum, das 
von der Induktion der Akut-Phase-Reaktion in der Leber bis zur Stimulation von B-Zellen zur 
Immunglobulinproduktion reicht. Auf Zielzellen bindet IL-6 zuerst an einen IL-6-spezifischen 
α-Rezeptor (IL-6R), woraufhin es zur Bindung und Dimerisierung der zweiten 
Rezeptoruntereinheit gp130 kommt. Neben dem membranständigen IL-6R existiert auch eine 
lösliche Form (sIL-6R), die entweder durch proteolytische Spaltung oder alternatives Spleißen 
entsteht. Der Komplex aus IL-6 und sIL-6R kann Zellen stimulieren, die lediglich gp130, aber 
keinen IL-6R tragen (IL-6-transsignaling). IL-6-transsignaling kann durch eine lösliche Form 
von gp130 (sgp130), die natürlicherweise im menschlichen Körper vorkommt, selektiv 
gehemmt werden. Viele Entzündungskrankheiten und Krebsformen beruhen auf IL-6-
transsignaling und sgp130 wird in diesem Zusammenhang ein hohes therapeutisches Potential 
bei der Behandlung dieser Krankheiten zugesprochen. 
Im Rahmen dieser Arbeit wurden transgene Mäuse generiert, die sgp130Fc unter der 
Kontrolle eines leberspezifischen Promotors exprimieren. Sgp130Fc ist ein Fusionsprotein, 
das aus dem extrazellulären Teil von gp130 und dem Fc-Teil eines humanen IgG-Antikörpers 
besteht. In transgenen Mäusen der „ersten Generation“ wurden vergleichsweise geringe 
Mengen von sgp130Fc im Serum gefunden (<0.55 µg/ml), welche nicht ausreichten, um 
murines IL-6-transsignaling zu inhibieren (Induktion der Akut-Phase-Antwort nach Hyper-IL-
6-Injektion). Daraufhin wurden neue transgene Mäuse generiert, die sgp130Fc nun von einer 
codon-optimierten cDNA exprimierten. Die Tiere der „zweiten Generation“ wiesen einen 
mehr als 50-fachen Anstieg der Konzentration von sgp130Fc im Serum auf (≤ 34.4 µg/ml), 
der ausreichend war, um IL-6-transsignaling in der Maus zu hemmen. Im Northern blot 
konnte gezeigt werden, daß sgp130Fc in der Leber, Niere, Lunge und im Muskel der 
transgenen Mäusen exprimiert wird. 
In einem Krankheitsmodell, bei dem künstlich eine akute Entzündungsreaktion in der Maus 
hervorgerufen wird (Air-pouch-Modell), konnte nachgewiesen werden, daß die Akkumulation 
von Leukozyten am Ort der Entzündung in sgp130Fc-transgenen Mäusen stark beinträchtigt 
ist. Es stellte sich heraus, daß insbesondere die Akkumulation von Neutrophilen und 
Makrophagen im späteren Entzündungsverlauf gestört ist. Dies ging mit einer reduzierten 
Produktion des Chemokins MCP-1 am Entzündungsherd einher. Zu Beginn der Entzündung 
wurden hohe Konzentrationen von IL-6 nachgewiesen, wohingegen die Menge an löslichem 
IL-6R erst im späteren Verlauf der Entzündung anstieg. Weiterhin konnte mit Hilfe von 
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neutropenischen Mäusen gezeigt werden, daß der lösliche IL-6R von Neutrophilen stammt, 
die in den Entzündungsherd eingewandert sind. Die Ergebnisse dieser Arbeit deuten 
daraufhin, daß das IL-6-transsignaling den Übergang von der anfänglichen, von Neutrophilen 
dominierten Phase zur späteren, mononukleären Phase einer akuten Entzündung vermittelt. 
Somit spielt der lösliche IL-6R eine entscheidende Rolle bei der erfolgreichen Auflösung 
einer akuten entzündlichen Reaktion. 
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8 Appendix 
 
8.1  Sequences 
 
A Nucleotide and amino acid sequence of the transgene expression cassette  
 pEPCK-sgp130Fc 
 
 
    1 GTTCCTGGCC TTTTGCTGGC CTTTTGCTCA CATGTTCTTT CCTGCGTTTT 
 
   51 CCCCTGATTC TGTGGATAAC CGTATTNCCG CCTTTGAGTG AGCTGATACC 
 
  101 GCTCGCCGCA GCCGAACGAC CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC 
 
  151 GGAAGAGCGC CCAATACGCA AACCGCCTCT CCCCGCGCGT TGGCCGATTC 
 
  201 ATTAATGCAG CTGGCACGAC AGGTTTCCCG ACTGGAAAGC GGGCAGTGAG 
 
  251 CGCAACGCAA TTAATGTGAG TTAGCTCACT CATTAGGCAC CCCAGGCTTT 
 
  301 ACACTTTATG CTTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC 
 
  351 AATTTCACAC AGGAAACAGC TATGACATGA TTACGAATTT AATACGACTC 
 
                             BamHI 
  401 ACTATAGGGA ATTCGCTAGT AGGATCCTAA GTAGCTGGAA TTCCCTTCTC 
 
  451 ATGACCTTTG GCCGTGGGAG TGACACCTCA CAGCTGTGGT GTTTTGACAA 
 
  501 CCAGCAGCCA CTGGCACACA AAATGTGCAG CCAGCAGCAT ATGAAGTCCA 
 
  551 AGAGGCGTCC CGGCCAGCCC TGTCCTTGAC CCCCACCTGA CAATTAAGGC 
 
  601 AAGAGCCTAT AGTTTGCATC AGCAACAGTC ACGGTCAAAG TTTAGTCAAT 
 
  651 CAAACGTTGT GTAAGGACTC AACTATGGCT GACACGGGGG CCTGAGGCCT 
 
  701 CCCAACATTC ATTAACAACA GCAAGTTCAA TCATTATCTC CCCAAAGTTT 
 
                                        NcoI 
  751 ATTGTGTTAG GTCAGTTCCA AACCGTGCTG ACCATGGCTA TGATCCAAAG 
 
  801 GCCGGCCCCT TACGTCAGAG GCGAGCCTCC AGGTCCAGCT GAGGGGCAGG 
 
  851 GCTGTCCTCC CTTCNTGTAT ACTATTTAAA GCGAGGAGGG CTAGCTACCA 
 
  901 AGCACGGTTG GCCTTCCCTC TGGGAACACA CCCTTGGCCA ACAGGGGAAA 
 
                               XbaI 
  951 TCCGGCGAGA CGCTCTGAGA TCCTCTAGAC CCCGCAAGAT GTTGACGTTG 
                                               M   L  T  L      
 
 1001 CAGACTTGGG TAGTGCAAGC CTTGTTTATT TTCCTCACCA CTGAATCTAC 
      Q  T  W  V   V  Q  A   L  F  I   F  L  T  T   E  S  T     
 
    
  93
            XbaI 
 1051 AGGTGAACTT CTAGATCCAT GTGGTTATAT CAGTCCTGAA TCTCCAGTTG 
       G  E  L   L  D  P  C   G  Y  I   S  P  E   S  P  V  V    
 
 1101 TACAACTTCA TTCTAATTTC ACTGCAGTTT GTGTGCTAAA GGAAAAATGT 
        Q  L  H   S  N  F   T  A  V  C   V  L  K   E  K  C      
 
 1151 ATGGATTATT TTCATGTAAA TGCTAATTAC ATTGTCTGGA AAACAAACCA 
      M  D  Y  F   H  V  N   A  N  Y   I  V  W  K   T  N  H     
 
 1201 TTTTACTATT CCTAAGGAGC AATATACTAT CATAAACAGA ACAGCATCCA 
       F  T  I   P  K  E  Q   Y  T  I   I  N  R   T  A  S  S    
 
 1251 GTGTCACCTT TACAGATATA GCTTCATTAA ATATTCAGCT CACTTGCAAC 
        V  T  F   T  D  I   A  S  L  N   I  Q  L   T  C  N      
 
 1301 ATTCTTACAT TCGGACAGCT TGAACAGAAT GTTTATGGAA TCACAATAAT 
      I  L  T  F   G  Q  L   E  Q  N   V  Y  G  I   T  I  I     
 
 1351 TTCAGGCTTG CCTCCAGAAA AACCTAAAAA TTTGAGTTGC ATTGTGAACG 
       S  G  L   P  P  E  K   P  K  N   L  S  C   I  V  N  E    
 
 1401 AGGGGAAGAA AATGAGGTGT GAGTGGGATG GTGGAAGGGA AACACACTTG 
        G  K  K   M  R  C   E  W  D  G   G  R  E   T  H  L      
 
 1451 GAGACAAACT TCACTTTAAA ATCTGAATGG GCAACACACA AGTTTGCTGA 
      E  T  N  F   T  L  K   S  E  W   A  T  H  K   F  A  D     
 
 1501 TTGCAAAGCA AAACGTGACA CCCCCACCTC ATGCACTGTT GATTATTCTA 
       C  K  A   K  R  D  T   P  T  S   C  T  V   D  Y  S  T    
 
 1551 CTGTGTATTT TGTCAACATT GAAGTCTGGG TAGAAGCAGA GAATGCCCTT 
        V  Y  F   V  N  I   E  V  W  V   E  A  E   N  A  L      
 
 1601 GGGAAGGTTA CATCAGATCA TATCAATTTT GATCCTGTAT ATAAAGTGAA 
      G  K  V  T   S  D  H   I  N  F   D  P  V  Y   K  V  K     
 
 1651 GCCCAATCCG CCACATAATT TATCAGTGAT CAACTCAGAG GAACTGTCTA 
       P  N  P   P  H  N  L   S  V  I   N  S  E   E  L  S  S    
 
 1701 GTATCTTAAA ATTGACATGG ACCAACCCAA GTATTAAGAG TGTTATAATA 
        I  L  K   L  T  W   T  N  P  S   I  K  S   V  I  I      
 
 1751 CTAAAATATA ACATTCAATA TAGGACCAAA GATGCCTCAA CTTGGAGCCA 
      L  K  Y  N   I  Q  Y   R  T  K   D  A  S  T   W  S  Q     
 
 1801 GATTCCTCCT GAAGACACAG CATCCACCCG ATCTTCATTC ACTGTCCAAG 
       I  P  P   E  D  T  A   S  T  R   S  S  F   T  V  Q  D    
 
 1851 ACCTTAAACC TTTTACAGAA TATGTGTTTA GGATTCGCTG TATGAAGGAA 
        L  K  P   F  T  E   Y  V  F  R   I  R  C   M  K  E      
 
 1901 GATGGTAAGG GATACTGGAG TGACTGGAGT GAAGAAGCAA GTGGGATCAC 
      D  G  K  G   Y  W  S   D  W  S   E  E  A  S   G  I  T     
 
 1951 CTATGAAGAT AGACCATCTA AAGCACCAAG TTTCTGGTAT AAAATAGATC 
       Y  E  D   R  P  S  K   A  P  S   F  W  Y   K  I  D  P    
 
 2001 CATCCCATAC TCAAGGCTAC AGAACTGTAC AACTCGTGTG GAAGACATTG 
        S  H  T   Q  G  Y   R  T  V  Q   L  V  W   K  T  L      
 
 2051 CCTCCTTTTG AAGCCAATGG AAAAATCTTG GATTATGAAG TGACTCTCAC 
      P  P  F  E   A  N  G   K  I  L   D  Y  E  V   T  L  T     
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 2101 AAGATGGAAA TCACATTTAC AAAATTACAC AGTTAATGCC ACAAAACTGA 
       R  W  K   S  H  L  Q   N  Y  T   V  N  A   T  K  L  T    
 
 2151 CAGTAAATCT CACAAATGAT CGCTATCTAG CAACCCTAAC AGTAAGAAAT 
        V  N  L   T  N  D   R  Y  L  A   T  L  T   V  R  N      
 
 2201 CTTGTTGGCA AATCAGATGC AGCTGTTTTA ACTATCCCTG CCTGTGACTT 
      L  V  G  K   S  D  A   A  V  L   T  I  P  A   C  D  F     
 
 2251 TCAAGCTACT CACCCTGTAA TGGATCTTAA AGCATTCCCC AAAGATAACA 
       Q  A  T   H  P  V  M   D  L  K   A  F  P   K  D  N  M    
 
 2301 TGCTTTGGGT GGAATGGACT ACTCCAAGGG AATCTGTAAA GAAATATATA 
        L  W  V   E  W  T   T  P  R  E   S  V  K   K  Y  I      
 
 2351 CTTGAGTGGT GTGTGTTATC AGATAAAGCA CCCTGTATCA CAGACTGGCA 
      L  E  W  C   V  L  S   D  K  A   P  C  I  T   D  W  Q     
 
 2401 ACAAGAAGAT GGTACCGTGC ATCGCACCTA TTTAAGAGGG AACTTAGCAG 
       Q  E  D   G  T  V  H   R  T  Y   L  R  G   N  L  A  E    
 
 2451 AGAGCAAATG CTATTTGATA ACAGTTACTC CAGTATATGC TGATGGACCA 
        S  K  C   Y  L  I   T  V  T  P   V  Y  A   D  G  P      
 
 2501 GGAAGCCCTG AATCCATAAA GGCATACCTT AAACAAGCTC CACCTTCCAA 
      G  S  P  E   S  I  K   A  Y  L   K  Q  A  P   P  S  K     
 
 2551 AGGACCTACT GTTCGGACAA AAAAAGTAGG GAAAAACGAA GCTGTCTTAG 
       G  P  T   V  R  T  K   K  V  G   K  N  E   A  V  L  E    
 
 2601 AGTGGGACCA ACTTCCTGTT GATGTTCAGA ATGGATTTAT CAGAAATTAT 
        W  D  Q   L  P  V   D  V  Q  N   G  F  I   R  N  Y      
 
 2651 ACTATATTTT ATAGAACCAT CATTGGAAAT GAAACTGCTG TGAATGTGGA 
      T  I  F  Y   R  T  I   I  G  N   E  T  A  V   N  V  D     
 
 2701 TTCTTCCCAC ACAGAATATA CATTGTCCTC TTTGACTAGT GACACATTGT 
       S  S  H   T  E  Y  T   L  S  S   L  T  S   D  T  L  Y    
 
 2751 ACATGGTACG AATGGCAGCA TACACAGATG AAGGTGGGAA GGATGGTCCA 
        M  V  R   M  A  A   Y  T  D  E   G  G  K   D  G  P      
 
 2801 GAATTCAGAT CTTGTGACAA AACTCACACA TGCCCACCGT GCCCAGCACC 
      E  F  R  S   C  D  K   T  H  T   C  P  P  C   P  A  P     
 
 2851 TGAAGCCGAG GGCGCGCCGT CAGTCTTCCT CTTCCCCCCA AAACCCAAGG 
       E  A  E   G  A  P  S   V  F  L   F  P  P   K  P  K  D    
 
 2901 ACACCCTCAT GATCTCCCGG ACCCCTGAGG TCACATGCGT GGTGGTGGAC 
        T  L  M   I  S  R   T  P  E  V   T  C  V   V  V  D      
 
 2951 GTGAGCCACG AAGACCCTGA GGTCAAGTTC AACTGGTACG TGGACGGCGT 
      V  S  H  E   D  P  E   V  K  F   N  W  Y  V   D  G  V     
 
 3001 GGAGGTGCAT AATGCCAAGA CAAAGCCGCG GGAGGAGCAG TACAACAGCA 
       E  V  H   N  A  K  T   K  P  R   E  E  Q   Y  N  S  T    
 
 3051 CGTACCGTGT GGTCAGCGTC CTCACCGTCC TGCACCAGGA CTGGCTGAAT 
        Y  R  V   V  S  V   L  T  V  L   H  Q  D   W  L  N      
 
 3101 GGCAAGGAGT ACAAGTGCAA GGTCTCCAAC AAAGCCCTCC CAGCCCCCAT 
      G  K  E  Y   K  C  K   V  S  N   K  A  L  P   A  P  I     
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 3151 CGAGAAAACC ATCTCCAAAG CCAAAGGGCA GCCCCGAGAA CCACAGGTGT 
       E  K  T   I  S  K  A   K  G  Q   P  R  E   P  Q  V  Y    
 
 3201 ACACCCTGCC CCCATCCCGG GAGGAGATGA CCAAGAACCA GGTCAGCCTG 
        T  L  P   P  S  R   E  E  M  T   K  N  Q   V  S  L      
 
 3251 ACCTGCCTGG TCAAAGGCTT CTATCCCAGC GACATCGCCG TGGAGTGGGA 
      T  C  L  V   K  G  F   Y  P  S   D  I  A  V   E  W  E     
 
 3301 GAGCAATGGG CAGCCGGAGA ACAACTACAA GACCACGCCT CCCGTGCTGG 
       S  N  G   Q  P  E  N   N  Y  K   T  T  P   P  V  L  D    
 
 3351 ACTCCGACGG CTCCTTCTTC CTCTATAGCA AGCTCACCGT GGACAAGAGC 
        S  D  G   S  F  F   L  Y  S  K   L  T  V   D  K  S      
 
 3401 AGGTGGCAGC AGGGGAACGT CTTCTCATGC TCCGTGATGC ATGAGGCTCT 
      R  W  Q  Q   G  N  V   F  S  C   S  V  M  H   E  A  L     
 
 3451 GCACAACCAC TACACGCAGA AGAGCCTCTC CCTGTCTCCG GGTAAATGAA 
       H  N  H   Y  T  Q  K   S  L  S   L  S  P   G  K  *   
 
           XbaI 
 3501 CTAGTTCTAG AGTCGACCGA TCCTGAGAAC TTCAGGGTGA GTTTGGGGAC 
 
 3551 CCTTGATTGT TCTTTCTTTT TCGCTATTGT AAAATTCATG TTATATGGAG 
 
 3601 GGGGCAAAGT TTTCAGGGTG TTGTTTAGAA TGGGAAGATG TCCCTTGTAT 
 
        NcoI 
 3651 CACCATGGAC CCTCATGATA ATNGTGTTTC TTTCACTTTC TACTCTGTTG 
 
 3701 ACAACCATTG TCTCCTCTTA TTTTCTTTTC ATTTTCTGTA ACTTTTTCGT 
 
 3751 TAAACTTTAG CTTGCATTTG TAACGAATTT TTAAATTCAC TTTTGTTTAT 
 
 3801 TTGTCAGATT GTAAGTACTT TCTCTAATCA CTTTTTTTTC AAGGCAATCA 
 
 3851 GGGTATATTA TATTGTACTT CAGCACAGTT TTAGAGAACA ATTGTTATAA 
 
 3901 TTAAATGATA AGGTAGAATA TTTCTGCATA TAAATTCTGG CTGGCGTGGA 
 
 3951 AATATTCTTA TTGGTAGAAA CAACTACACC CTGGTCATCA TCCTGCCTTT 
 
 4001 CTCTTTATGG TTCAATGATA TACACTGTTT GAGATGAGGA TAAAATCTCT 
 
 4051 GAGTCCAAAC CGGGCCCCTC TGCTAACCAT GTTCATGCCT TCTTCTCTTT 
 
 4101 CCTCAGCTNC TGGGCACGGC TGGTTGTGTG CTGTCTCATC ATTTGGCAAG 
 
          XhoI 
 4151 AATCCTCGAG GATTCACTCC TCAGGTGCAG GCTGCCTATC AGAAGGTGGT 
 
 4201 GGCTGGTGTG GCCAATGCCC TGGCTCACAA ATACCACTGA GATCTTTTTC 
 
 4251 CCTCTGCCAA AAATTATGGG GACATCATGA AGCCCCTTGA GCATCTGACT 
 
 4301 TCTGGCTAAT AAAGGAAATT TATTTTCATT GCAATAGTGT GTTGGAATTT 
 
 4351 TTTGTGTCTC TCACTCGGAA GGACATATGG GAGGGCAAAT CATTTAAAAC 
 
 4401 ATCAGAATGA GTATTTGGTT TAGAGTTTGG CAACATATGC CCATATGCTG 
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 4451 GCTGCCATGA ACAAAGGTTG GCTATAAAGA GGTCATCAGT ATATGAAACA 
 
 4501 GCCCCCTGCT GTCCATTCCT TATTCCATAG AAAAGCCTTG ACTTGAGGTT 
 
 4551 AGATTTTTTT TATATTTTGT TTTGTGTTAT TTTTTTCTTT AACATCCCTA 
 
 4601 AAATTTTCCT TACATGTTTT ACTAGCCAGA TTTTTCCTCC TCTCCTGACT 
 
                                                        BamHI 
 4651 ACTCCCAGTC ATAGCTGTCC CTCTTCTCTT ATGGAGATCC CTCGACGGAT 
 
 4701 CCTGAGAACT TCAGGGTGAG TCTATGGGAC CCTTGATGTT TTCTTTCCCC 
 
 4751 TTCTTTTCTA TGGTTAAGTT CATGTCATAG GAAGGGGAGA AGTAACAGGG 
 
 4801 TACAGTTTAG AATGGGAAAC AGACGAATGA TTGCATCAGT GTGGAAGTCT 
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B Nucleotide and amino acid sequence of the transgene expression cassette  
 pEPCK-sgp130Fc/opt-XhoI 
 
 
    1 GTTCCTGGCC TTTTGCTGGC CTTTTGCTCA CATGTTCTTT CCTGCGTTTT 
 
   51 CCCCTGATTC TGTGGATAAC CGTATTNCCG CCTTTGAGTG AGCTGATACC 
 
  101 GCTCGCCGCA GCCGAACGAC CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC 
 
       EarI 
  151 GGAAGAGCGC CCAATACGCA AACCGCCTCT CCCCGCGCGT TGGCCGATTC 
 
  201 ATTAATGCAG CTGGCACGAC AGGTTTCCCG ACTGGAAAGC GGGCAGTGAG 
 
  251 CGCAACGCAA TTAATGTGAG TTAGCTCACT CATTAGGCAC CCCAGGCTTT 
 
  301 ACACTTTATG CTTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC 
 
  351 AATTTCACAC AGGAAACAGC TATGACATGA TTACGAATTT AATACGACTC 
 
  401 ACTATAGGGA ATTCGCTAGT AGGATCCTAA GTAGCTGGAA TTCCCTTCTC 
 
  451 ATGACCTTTG GCCGTGGGAG TGACACCTCA CAGCTGTGGT GTTTTGACAA 
 
  501 CCAGCAGCCA CTGGCACACA AAATGTGCAG CCAGCAGCAT ATGAAGTCCA 
 
  551 AGAGGCGTCC CGGCCAGCCC TGTCCTTGAC CCCCACCTGA CAATTAAGGC 
 
  601 AAGAGCCTAT AGTTTGCATC AGCAACAGTC ACGGTCAAAG TTTAGTCAAT 
 
  651 CAAACGTTGT GTAAGGACTC AACTATGGCT GACACGGGGG CCTGAGGCCT 
 
  701 CCCAACATTC ATTAACAACA GCAAGTTCAA TCATTATCTC CCCAAAGTTT 
 
  751 ATTGTGTTAG GTCAGTTCCA AACCGTGCTG ACCATGGCTA TGATCCAAAG 
 
  801 GCCGGCCCCT TACGTCAGAG GCGAGCCTCC AGGTCCAGCT GAGGGGCAGG 
 
  851 GCTGTCCTCC CTTCNTGTAT ACTATTTAAA GCGAGGAGGG CTAGCTACCA 
 
  901 AGCACGGTTG GCCTTCCCTC TGGGAACACA CCCTTGGCCA ACAGGGGAAA 
 
                               XbaI 
  951 TCCGGCGAGA CGCTCTGAGA TCCTCTAGAG TCGACCGATC CTGAGAACTT 
 
 1001 CAGGGTGAGT TTGGGGACCC TTGATTGTTC TTTCTTTTTC GCTATTGTAA 
 
 1051 AATTCATGTT ATATGGAGGG GGCAAAGTTT TCAGGGTGTT GTTTAGAATG 
 
 1101 GGAAGATGTC CCTTGTATCA CCATGGACCC TCATGATAAT NGTGTTTCTT 
 
 1151 TCACTTTCTA CTCTGTTGAC AACCATTGTC TCCTCTTATT TTCTTTTCAT 
 
 1201 TTTCTGTAAC TTTTTCGTTA AACTTTAGCT TGCATTTGTA ACGAATTTTT 
 
 1251 AAATTCACTT TTGTTTATTT GTCAGATTGT AAGTACTTTC TCTAATCACT 
 
 1301 TTTTTTTCAA GGCAATCAGG GTATATTATA TTGTACTTCA GCACAGTTTT 
 
 1351 AGAGAACAAT TGTTATAATT AAATGATAAG GTAGAATATT TCTGCATATA 
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 1401 AATTCTGGCT GGCGTGGAAA TATTCTTATT GGTAGAAACA ACTACACCCT 
 
 1451 GGTCATCATC CTGCCTTTCT CTTTATGGTT CAATGATATA CACTGTTTGA 
 
 1501 GATGAGGATA AAATCTCTGA GTCCAAACCG GGCCCCTCTG CTAACCATGT 
 
 1551 TCATGCCTTC TTCTCTTTCC TCAGCTNCTG GGCACGGCTG GTTGTGTGCT 
 
                              XhoI 
 1601 GTCTCATCAT TTGGCAAGAA TCCTCGAGGG CCACGCGTTT AAACGTCGAC 
 
 
 1651 AGATCTAAGC TTGCCACCAT GCTGACACTG CAGACATGGC TGGTGCAGGC 
                         M   L  T  L   Q  T  W  L   V  Q  A     
 
 1701 CCTGTTTATC TTTCTGACCA CCGAGTCTAC AGGAGAGCTG CTGGATCCTT 
       L  F  I   F  L  T  T   E  S  T   G  E  L   L  D  P  C    
 
 1751 GCGGCTATAT CTCCCCTGAG TCTCCTGTGG TGCAGCTGCA TTCTAACTTC 
        G  Y  I   S  P  E   S  P  V  V   Q  L  H   S  N  F      
 
 1801 ACCGCCGTGT GTGTGCTGAA GGAAAAGTGC ATGGACTACT TCCACGTGAA 
      T  A  V  C   V  L  K   E  K  C   M  D  Y  F   H  V  N     
 
 1851 CGCCAACTAC ATCGTGTGGA AAACCAACCA CTTCACCATC CCCAAGGAGC 
       A  N  Y   I  V  W  K   T  N  H   F  T  I   P  K  E  Q    
 
 1901 AGTACACCAT CATCAACCGG ACCGCTTCTT CTGTGACCTT CACCGATATC 
        Y  T  I   I  N  R   T  A  S  S   V  T  F   T  D  I      
 
 1951 GCCTCCCTGA ATATCCAGCT GACCTGCAAC ATCCTGACCT TTGGACAGCT 
      A  S  L  N   I  Q  L   T  C  N   I  L  T  F   G  Q  L     
 
 2001 GGAGCAGAAT GTGTACGGCA TCACCATCAT CTCTGGCCTG CCTCCAGAGA 
       E  Q  N   V  Y  G  I   T  I  I   S  G  L   P  P  E  K    
 
 2051 AGCCTAAGAA CCTGTCCTGC ATCGTGAATG AGGGCAAGAA GATGAGGTGT 
        P  K  N   L  S  C   I  V  N  E   G  K  K   M  R  C      
 
 2101 GAGTGGGATG GCGGCAGAGA GACACATCTG GAGACCAACT TCACCCTGAA 
      E  W  D  G   G  R  E   T  H  L   E  T  N  F   T  L  K     
 
 2151 GTCTGAGTGG GCCACCCACA AGTTTGCCGA CTGCAAGGCC AAGAGAGATA 
       S  E  W   A  T  H  K   F  A  D   C  K  A   K  R  D  T    
 
 2201 CCCCTACCTC TTGCACCGTG GACTACTCCA CCGTGTACTT CGTGAACATC 
        P  T  S   C  T  V   D  Y  S  T   V  Y  F   V  N  I      
 
 2251 GAGGTGTGGG TGGAGGCTGA GAATGCTCTG GGCAAGGTGA CCTCTGACCA 
      E  V  W  V   E  A  E   N  A  L   G  K  V  T   S  D  H     
  
 2301 CATCAACTTC GACCCCGTGT ACAAGGTGAA GCCTAACCCT CCTCACAACC 
       I  N  F   D  P  V  Y   K  V  K   P  N  P   P  H  N  L    
  
 2351 TGTCCGTGAT CAACTCTGAG GAGCTGTCCT CTATCCTGAA GCTGACCTGG 
        S  V  I   N  S  E   E  L  S  S   I  L  K   L  T  W      
 
 2401 ACCAACCCTT CCATCAAGTC CGTGATCATC CTGAAGTACA ACATCCAGTA 
      T  N  P  S   I  K  S   V  I  I   L  K  Y  N   I  Q  Y     
 
 2451 CAGGACCAAG GATGCTTCTA CCTGGTCTCA GATCCCTCCT GAGGATACCG 
       R  T  K   D  A  S  T   W  S  Q   I  P  P   E  D  T  A    
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 2501 CTTCCACCAG ATCCAGCTTC ACAGTGCAGG ACCTGAAGCC TTTTACCGAG 
        S  T  R   S  S  F   T  V  Q  D   L  K  P   F  T  E      
 
 2551 TACGTGTTCA GGATCCGGTG CATGAAGGAG GATGGCAAGG GCTATTGGTC 
      Y  V  F  R   I  R  C   M  K  E   D  G  K  G   Y  W  S     
 
 2601 TGACTGGTCT GAGGAGGCTT CTGGCATCAC CTACGAGGAC AGACCTTCTA 
       D  W  S   E  E  A  S   G  I  T   Y  E  D   R  P  S  K    
 
 2651 AGGCCCCTAG CTTCTGGTAC AAGATCGACC CTTCTCACAC CCAGGGCTAT 
        A  P  S   F  W  Y   K  I  D  P   S  H  T   Q  G  Y      
 
 2701 AGAACAGTGC AGCTGGTGTG GAAAACCCTG CCTCCATTCG AGGCTAATGG 
      R  T  V  Q   L  V  W   K  T  L   P  P  F  E   A  N  G     
 
 2751 CAAGATCCTG GACTATGAGG TGACCCTGAC CAGATGGAAG TCTCACCTGC 
       K  I  L   D  Y  E  V   T  L  T   R  W  K   S  H  L  Q    
 
 2801 AGAACTACAC CGTGAACGCT ACCAAGCTGA CCGTGAACCT GACCAACGAT 
        N  Y  T   V  N  A   T  K  L  T   V  N  L   T  N  D      
 
 2851 AGATACCTGG CTACCCTGAC CGTGAGAAAT CTGGTGGGCA AGTCTGATGC 
      R  Y  L  A   T  L  T   V  R  N   L  V  G  K   S  D  A     
 
 2901 TGCTGTGCTG ACCATCCCTG CCTGTGATTT TCAGGCTACC CACCCTGTGA 
       A  V  L   T  I  P  A   C  D  F   Q  A  T   H  P  V  M    
 
 2951 TGGATCTGAA GGCCTTCCCC AAGGATAACA TGCTGTGGGT GGAGTGGACA 
        D  L  K   A  F  P   K  D  N  M   L  W  V   E  W  T      
 
 3001 ACACCTAGAG AGTCCGTGAA GAAGTACATC CTGGAGTGGT GCGTGCTGTC 
      T  P  R  E   S  V  K   K  Y  I   L  E  W  C   V  L  S     
 
 3051 TGATAAGGCC CCTTGCATCA CAGATTGGCA GCAGGAGGAT GGCACCGTGC 
       D  K  A   P  C  I  T   D  W  Q   Q  E  D   G  T  V  H    
 
 3101 ATAGAACCTA CCTGAGAGGC AATCTGGCCG AGTCTAAGTG CTATCTGATC 
        R  T  Y   L  R  G   N  L  A  E   S  K  C   Y  L  I      
 
 3151 ACCGTGACCC CTGTGTATGC TGATGGACCT GGCTCTCCTG AGTCTATCAA 
      T  V  T  P   V  Y  A   D  G  P   G  S  P  E   S  I  K     
 
 3201 GGCCTACCTG AAGCAGGCTC CTCCATCTAA GGGACCTACC GTGAGGACAA 
       A  Y  L   K  Q  A  P   P  S  K   G  P  T   V  R  T  K    
 
 3251 AGAAGGTGGG CAAGAACGAG GCTGTGCTGG AGTGGGATCA GCTGCCTGTG 
        K  V  G   K  N  E   A  V  L  E   W  D  Q   L  P  V      
 
 3301 GATGTGCAGA ACGGCTTCAT CCGGAACTAC ACCATCTTCT ACCGGACCAT 
      D  V  Q  N   G  F  I   R  N  Y   T  I  F  Y   R  T  I     
 
 3351 CATCGGCAAT GAGACCGCCG TGAACGTGGA TTCTTCCCAC ACCGAGTACA 
       I  G  N   E  T  A  V   N  V  D   S  S  H   T  E  Y  T    
 
 3401 CACTGTCCTC TCTGACCTCT GACACCCTGT ACATGGTGAG AATGGCCGCT 
        L  S  S   L  T  S   D  T  L  Y   M  V  R   M  A  A      
 
 3451 TATACCGATG AGGGCGGCAA GGATGGACCT GAGTTCAGAT CCTGCGACAA 
      Y  T  D  E   G  G  K   D  G  P   E  F  R  S   C  D  K     
 
 3501 GACCCACACC TGTCCTCCTT GTCCTGCTCC TGAGGCTGAG GGCGCTCCTT 
       T  H  T   C  P  P  C   P  A  P   E  A  E   G  A  P  S    
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 3551 CTGTGTTTCT GTTCCCCCCA AAGCCTAAGG ATACCCTGAT GATCTCCAGA 
        V  F  L   F  P  P   K  P  K  D   T  L  M   I  S  R      
 
 3601 ACCCCTGAGG TGACATGTGT GGTGGTGGAT GTGTCTCATG AGGACCCCGA 
      T  P  E  V   T  C  V   V  V  D   V  S  H  E   D  P  E     
 
 3651 GGTGAAGTTC AACTGGTACG TGGATGGCGT GGAGGTGCAC AATGCTAAGA 
       V  K  F   N  W  Y  V   D  G  V   E  V  H   N  A  K  T    
 
 3701 CCAAGCCTAG GGAGGAGCAG TACAACTCCA CCTACAGAGT GGTGTCTGTG 
        K  P  R   E  E  Q   Y  N  S  T   Y  R  V   V  S  V      
 
 3751 CTGACAGTGC TGCATCAGGA TTGGCTGAAC GGCAAGGAGT ACAAGTGCAA 
      L  T  V  L   H  Q  D   W  L  N   G  K  E  Y   K  C  K     
 
 3801 GGTGTCCAAC AAGGCTCTGC CTGCTCCTAT CGAAAAGACC ATCTCCAAGG 
       V  S  N   K  A  L  P   A  P  I   E  K  T   I  S  K  A    
 
 3851 CTAAGGGACA GCCTAGAGAG CCTCAGGTGT ACACACTGCC TCCATCTAGG 
        K  G  Q   P  R  E   P  Q  V  Y   T  L  P   P  S  R      
 
 3901 GAGGAGATGA CCAAGAATCA GGTGTCCCTG ACCTGTCTGG TGAAGGGCTT 
      E  E  M  T   K  N  Q   V  S  L   T  C  L  V   K  G  F     
 
 3951 CTACCCTTCT GATATCGCTG TGGAGTGGGA GTCTAATGGC CAGCCCGAGA 
       Y  P  S   D  I  A  V   E  W  E   S  N  G   Q  P  E  N    
 
 4001 ACAATTACAA GACCACCCCT CCTGTGCTGG ATTCTGACGG CTCCTTCTTC 
        N  Y  K   T  T  P   P  V  L  D   S  D  G   S  F  F      
 
 4051 CTGTACTCCA AACTGACCGT GGACAAGTCT AGATGGCAGC AGGGCAACGT 
      L  Y  S  K   L  T  V   D  K  S   R  W  Q  Q   G  N  V     
 
 4101 GTTCTCTTGT TCCGTGATGC ACGAGGCTCT GCACAATCAC TATACCCAGA 
       F  S  C   S  V  M  H   E  A  L   H  N  H   Y  T  Q  K    
 
                                              XhoI 
 4151 AGTCCCTGTC TCTGTCTCCT GGCAAGTGAT GAGAATTCTC GAGGATTCAC 
        S  L  S   L  S  P   G  K  *     
 
 4201 TCCTCAGGTG CAGGCTGCCT ATCAGAAGGT GGTGGCTGGT GTGGCCAATG 
 
 4251 CCCTGGCTCA CAAATACCAC TGAGATCTTT TTCCCTCTGC CAAAAATTAT 
 
 4301 GGGGACATCA TGAAGCCCCT TGAGCATCTG ACTTCTGGCT AATAAAGGAA 
 
 4351 ATTTATTTTC ATTGCAATAG TGTGTTGGAA TTTTTTGTGT CTCTCACTCG 
 
 4401 GAAGGACATA TGGGAGGGCA AATCATTTAA AACATCAGAA TGAGTATTTG 
 
 4451 GTTTAGAGTT TGGCAACATA TGCCCATATG CTGGCTGCCA TGAACAAAGG 
 
 4501 TTGGCTATAA AGAGGTCATC AGTATATGAA ACAGCCCCCT GCTGTCCATT 
 
 4551 CCTTATTCCA TAGAAAAGCC TTGACTTGAG GTTAGATTTT TTTTATATTT 
 
 4601 TGTTTTGTGT TATTTTTTTC TTTAACATCC CTAAAATTTT CCTTACATGT 
 
 4651 TTTACTAGCC AGATTTTTCC TCCTCTCCTG ACTACTCCCA GTCATAGCTG 
 
         EarI 
 4701 TCCCTCTTCT CTTATGGAGA TCCCTCGACG GATCCTGAGA ACTTCAGGGT 
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 4751 GAGTCTATGG GACCCTTGAT GTTTTCTTTC CCCTTCTTTT CTATGGTTAA 
 
 4801 GTTCATGTCA TAGGAAGGGG AGAAGTAACA GGGTACAGTT TAGAATGGGA 
 
 4851 AACAGACGAA TGATTGCATC AGTGTGGAAG TCTCAGGATC GNTTTAGTTT 
 
 4901 CCTTTTATTT GCTGNTCATA ACAANTGGTT TNC                   
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8.2 Vector maps 
 
A pEPCK-sgp130Fc 
pEPCK-sgp130Fc
9.4 kb
Ampicillin
rat PEPCK
promoter
sgp130Fc
2nd intron
rabbit β-globin
polyA 
rabbit β-globin
BamHI
BamHI
XbaI
XbaI
XhoI
 
 
 
 
B pEPCK-sgp130Fc/opt-XhoI   
 
pEPCK-
sgp130Fc/opt-XhoI
9.4 kb
2nd intron
rabbit β-globin
sgp130Fc/opt
rat PEPCK
promoter
polyA 
rabbit β-globin
Ampicillin
EarI
EarI
XbaI
XhoI
XhoI
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8.3  Abbreviations 
 
ADAM - a disintegrin and metalloprotease 
Ag – antigen 
Amp – ampicillin 
AP – alkaline phosphatase 
APC - allophycocyanin 
APP – acute phase protein 
APS – ammonium persulfate 
ATCC - American Type Culture Collection 
Bcl-2 - B-cell lymphoma 2 
BSA – bovine serum albumine 
CBM - cytokine-binding module 
CD – cluster of differentiation 
cDNA – complementary DNA 
CIAP - calf intestine alkaline phosphatase 
CLC - cardiotrophin-like cytokine 
CNTF - ciliary neurotrophic factor 
CT-1 – cardiotrophin-1 
dATP - deoxy adenosine triphosphate  
DEAE – diethylaminoethyl 
DNA - deoxyribonucleic acid 
DMSO – dimethylsulfoxide 
EDTA – ethylendiamintetraacetic acid 
ELISA – enzyme linked immunosorbent assay 
ER – endoplasmic reticulum 
FACS - fluorescence-activated cell-sorting 
FCS – fetal calf serum 
Fig - figure 
FITC – fluorescein isothiocyanate 
FRET - fluorescence resonance energy transfer 
GFP – green fluorescent protein 
gp – glycoprotein 
Grb2 - growth-factor-receptor-bound protein 
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Groα - growth-related oncogene α 
h - hour 
HHV-8 – human herpesvirus-8 
H-IL-6 – Hyperinterleukin-6 
his – histidin 
hIL-6 – human interleukin-6 
ICAM-1 - intercellular adhesion molecule-1 
IFNα, γ – interferon α, γ 
IgG – immunoglobulin G 
IL – interleukin 
IP - immunoprecipitation 
JAK – janus-kinase 
kb – kilobase pairs 
kD – kilodalton 
kg - kilogram 
KS – Kaposi’s sarcoma 
KSHV - Kaposi’s sarcoma associated herpesvirus 
l – liter 
LB - lysogeny broth 
LIF - leukemia inhibitory factor 
LPS - lipopolysaccharide 
MCP-1/3 - Monocyte chemoattractant protein-1/3 
mAB – monoclonal antibody  
MAPK - mitogen ativated protein kinase 
MCD - multicentric Castleman’s disease 
mg – milligram 
µg - microgram 
min - minute 
MM – multiple myeloma 
ml - milliliter 
Mr – molecular weight 
mRNA – messenger RNA 
ng - nanogramm 
NF – nuclear factor 
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NPN - new neuropoietin 
OD – optic density 
o/n – over night 
ORF – open reading frame 
OSM – oncostatin M  
PBS - phosphate buffered saline 
PCR – polymerase chain reaction 
PEL - primary effusion lymphoma 
PEPCK - phosphoenolpyruvate-carboxykinase 
pNPP – 4-nitrophenyl phosphate 
POD - peroxidase 
P-STAT3 - phospho-STAT3 
RA - rheumatoid arthritis 
RNA - ribonucleic acid 
rpm – round per minute 
RT – room temperatute 
RT-PCR - reverse transcription polymerase chain reaction 
SAA – serum amyloid A 
SD - standard deviation 
SDS – sodium dodecyl sulfate 
SDS-PAGE - sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
sec - second 
sgp130 – soluble glycoprotein 130 
sIL-6R - soluble interleukin-6 receptor 
SOCS – suppressor of cytokine signaling 
ssDNA – single stranded DNA 
STAT - signal transducer and activator of transcription 
TACE - TNFα converting enzyme 
TBS – tris buffered saline 
TEMED – N,N,N’,N’-tetraethylenamine 
tg - transgenic 
TGFβ - transforming growth factor β 
T
m – melting temperature 
TNFα – tumor necrosis factor α 
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UV - ultraviolet 
VCAM-1 - vascular cell adhesion molecule-1 
vIL-6 – viral interleukin-6 
WT - wildtype 
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